

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A01N 65/00, 31/08, A61K 9/48, 9/20, 9/22, 9/28	A1	(11) International Publication Number: WO 98/16111 (43) International Publication Date: 23 April 1998 (23.04.98)
(21) International Application Number: PCT/US97/18845 (22) International Filing Date: 14 October 1997 (14.10.97) (30) Priority Data: 08/730,772 16 October 1996 (16.10.96) US (71) Applicant: SHAMAN PHARMACEUTICALS, INC. [US/US]; 213 East Grand Avenue, South San Francisco, CA 94080 (US). (72) Inventors: ROZHON, Edward, J.; 523 San Carlos Avenue, El Granada, CA 94018-2291 (US). KHANDWALA, Atul, S.; 4 Marigold Lane, San Carlos, CA 94070 (US). SABOUNI, Akram; 570 Sierra Street, Moss Beach, CA 94038 (US). (74) Agents: BALDWIN, Geraldine, F. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: ENTERIC FORMULATIONS OF PROANTHOCYANIDIN POLYMER ANTIDIARRHEAL COMPOSITIONS		
(57) Abstract Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. Methods for use of the formulations as well as methods for use of the proanthocyanidin polymer composition in combination with an effective amount of a compound effective either to inhibit secretion of stomach acid or to neutralize stomach acid are disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

WO 98/16111

PCT/US97/18845

**ENTERIC FORMULATIONS OF
PROANTHOCYANIDIN POLYMER ANTIDIARRHEAL COMPOSITIONS**

1. FIELD OF THE INVENTION

5 The present invention relates to pharmaceutical
formulations of proanthocyanidin polymeric compositions which
are effective for the treatment of diarrhea. In particular,
the invention relates to pharmaceutical formulations of a
proanthocyanidin polymeric composition, which has been
10 isolated from a Croton spp. or Calophyllum spp., which
formulations are effective for the treatment of secretory
diarrhea, particularly for the reduction of the fluid loss
and resulting dehydration associated with secretory
diarrheas. A preferred embodiment of the invention relates
15 to pharmaceutical formulations of proanthocyanidin polymeric
compositions which protect the compositions from the acid
environment of the stomach after oral administration, and
particularly those formulations which are enteric coated.

2. BACKGROUND OF THE INVENTION

20 Citation or identification of any reference in Section 2
or any other section of this application shall not be
construed as an admission that such reference is available as
prior art for the present invention.

25

2.1. SECRETORY DIARRHEAS

Secretory diarrheas, also called watery diarrheas, are a
major source of illness and mortality in developing
countries, particularly in infants and young children and
also affect a significant proportion of visitors from
30 developed to developing countries and can also affect any
person visiting a foreign country (called "traveler's
diarrhea"). Secretory diarrhea is characterized by the loss
of both fluid and electrolytes through the intestinal tract,
35 leading to serious and often life-threatening dehydration.
Secretory diarrhea is caused by a variety of bacterial, viral
and protozoal pathogens and also results from other non-

WO 98/16111

PCT/US97/18845

infectious etiologies such as ulcerative colitis, inflammatory bowel syndrome, and cancers and neoplasias of the gastrointestinal tract. In fact, it is believed that all types of diarrheal disease may have a secretory component.

- 5 Two major bacterial sources of secretory diarrhea are *Vibrio cholerae* and *Escherichia coli*. The enterotoxigenic types of *E. coli* represent an important source of secretory diarrhea in developing countries and are the major cause of traveler's diarrhea. Other strains of *E. coli* which cause
- 10 diarrhea include enterohemorrhagic, enteroinvasive, and enteropathogenic and other strains. Other bacterial agents which cause secretory diarrhea include other *Vibrio* spp., *Campylobacter* spp., *Salmonella* spp., *Aeromonas* spp., *Plesiomonas* spp., *Shigella* spp., *Klebsiella* spp., *Citrobacter*
- 15 spp., *Yersinia* spp., *Clostridium* spp., *Bacteriodes* spp., *Staphylococcus* spp., and *Bacillus* spp., as well as other enteric bacteria. Secretory diarrhea can also be caused by protozoal pathogens such as *Cryptosporidium* spp, for example *Cryptosporidium parvum*. See generally, Holland, 1990, *Clin. Microbiol. Rev.* 3:345; Harris, 1988, *Ann. Clin. Lab. Sci.* 18:102; Gracey, 1986, *Clin. in Gastroent.*, 15:21; Ooms and Degryse, 1986, *Veterinary Res. Comm.* 10:355; Black, 1982, *Med. Clin. Nor. Am.*, 66:611.

- V. cholerae*, the enterotoxigenic strains of *E. coli*, and
- 25 a variety of other enteric bacteria elicit secretory diarrhea via similar mechanisms. These pathogens produce a toxin which binds a specific receptor on the apical membrane of the intestinal epithelium. Binding of the receptor triggers an adenylate cyclase- or guanylate cyclase-mediated signal
- 30 transduction leading to an increase in cAMP or cGMP. This regulatory cascade, apparently acting through phosphorylation of specific apical membrane proteins, stimulates chloride efflux into the gut from the intestinal epithelial crypt cells and inhibits normal resorption of sodium and chloride
- 35 ions by the intestinal epithelial villus cells. The increased chloride and sodium ion concentration osmotically draws water into the intestinal lumen, resulting in both

WO 98/16111

PCT/US97/18845

dehydration and loss of electrolytes. Agents which reduce chloride ion secretion will, therefore, prevent the fluid movement into the intestine and resulting net fluid elimination. Thus, such agents are particularly useful for
5 treating and preventing the dangerous dehydration and electrolyte loss associated with secretory diarrhea.

The pharmaceutical compositions of the present invention are particularly useful for treatment of traveler's diarrhea and non-specific diarrhea. Traveler's diarrhea, which is a
10 type of secretory diarrhea, is defined as diarrhea experienced by citizens of industrialized nations who travel to "third world" countries. An example of traveler's diarrhea is diarrheal disease experienced by United States citizens that travel to Mexico for the first time and have
15 diarrhea within the 3-5 days of arrival (Castelli & Carose, 1995, *Chemotherapy* 4(supp. 1): 20-32). Bacteria are estimated to be responsible for 85% of traveler's diarrhea with enterotoxigenic *Escherichia coli* (ETEC), *Shigella* spp., and *Campylobacter jejuni* being the principal etiologic
20 agents. Protozoa and viruses also cause traveler's diarrhea but at lower frequencies than bacteria (DuPont, 1995, *Chemotherapy* 4(supp. 1):33-39). In Mexico, in the summer months (May to November), the predominant etiologic agent associated with traveler's diarrhea is ETEC, whereas in the
25 winter months, the principal organism is *Campylobacter jejuni* (DuPont, 1995, "Traveler's diarrhea", M. Blaser et al., eds., pp. 299-311, Raven Press, New York). Approximately 40% of first time United States travelers to Mexico experience traveler's diarrhea.

30 In contrast to traveler's diarrhea, non-specific diarrhea (NSD), which also appears to have a secretory component, is an acute endemic diarrheal disease experienced by indigenous populations. The attack rate of non-specific diarrhea in Mexican residents is 7% (H.L. DuPont, personal
35 communication). Unlike traveler's diarrhea, however, non-specific diarrhea generally does not respond to antibiotic therapy and the etiology is not known.

WO 98/16111

PCT/US97/18845

Since 1975, DuPont and colleagues at the University of Texas Health Sciences Center at Houston have conducted a series of clinical trials in Mexico to study the efficacy of a variety of antidiarrheal drugs. Based on the results of the placebo groups from these studies, they have been able to characterize the natural history of traveler's diarrhea and non-specific diarrhea in United States travelers and Mexican nationals, respectively. The data show clear differences in both the intensity and duration of diarrheal disease between patients who have traveler's diarrhea in the summer and patients with non-specific diarrhea. In 5 day evaluations, the duration of disease (mean time to last unformed stool from time of enrollment) was 69 hours for United States travelers compared to 38 hours for Mexican nationals ($p=0.0001$). If the total number of stools passed since the time of enrollment is analyzed (0-120 hours), travelers from the United States have 10.6 stools versus 5.6 stools for Mexican residents ($p=0.0001$) (H.L. DuPont, personal communication).

Although not as much data is available on traveler's diarrhea occurring in the winter months in Mexico, in general the diarrheal disease in new arrivals from the United States is similar to diarrhea experienced by United States residents who have been in Mexico for several months. It tends to be less severe than traveler's diarrhea in the summer, and more severe than non-specific diarrhea (H.L. DuPont, personal communication).

Secretory diarrheas are also associated with viral infections, such as, diarrheas which accompany Human Immunodeficiency Virus (HIV) infection and Acquired Immuno Deficiency Syndrome (AIDS), and rotavirus infection, in particular. Almost all AIDS patients suffer from diarrhea at some point during the course of the disease, and 30% of AIDS patients suffer from chronic diarrhea. The diarrhea that accompanies AIDS has been termed "HIV-Associated Chronic Diarrhea." This diarrheal component of HIV disease is thought to be caused, at least in some patients, by a

WO 98/16111

PCT/US97/18845

secondary infection of protozoal pathogens, particularly *Cryptosporidium* spp. Additionally, rotavirus infection is a substantial cause of diarrhea particularly in infants and young children in developing countries.

- 5 Secretory diarrhea is also a significant problem in non-human animals, particularly in farm animals, such as bovine animals, swine, sheep (ovine animals), poultry (such as chickens), and equine animals, and other domesticated animals such as canine animals and feline animals. Diarrheal
- 10 disease is particularly common in young and recently weaned farm animals. Diarrheal disease in farm animals, particularly food animals such as cattle, sheep and swine, is often caused by bacterial pathogens such as enterotoxigenic, enterohemorrhagic and other *E. coli*, *Salmonella* spp.,
- 15 *Clostridium perfringens*, *Bacteriodes fragilis*, *Campylobacter* spp., and *Yersinia enterocolitica*. Additionally, protozoal pathogens, particularly *Cryptosporidium parvum*, and viral agents, particularly rotaviruses and coronaviruses, are significant causes of diarrhea in farm animals. Other viral
- 20 agents which have been implicated in diarrhea of farm animals include togavirus, parvovirus, calicivirus, adenoviruses, bredaviruses, and astroviruses. See generally Holland, 1990, *Clin. Microbiology Rev.* 3:345; see also Gutzwiller and Blum, 1996, *AJVR* 57:560; Strombeck, 1995, *Veterinary Quarterly*
- 25 17(Suppl. 1):S12; Vermunt, 1994, *Austral. Veterinary J.* 71:33; Driesen et al., 1993, *Austral. Veterinary J.* 70:259; Mouricout, 1991, *Eur. J. Epidemiol.* 7:588; Ooms and Degryse, 1986, *Veterinary Res. Comm.* 10:355.

30 **2.2. PLANT EXTRACTS CONTAINING TANNINS OR
PROANTHOCYANIDINS AND USE AGAINST DIARRHEA**

- Tannins are found in a wide variety of plants and are classified as either hydrolyzable or condensed.
- Proanthocyanidins are a group of condensed tannins and are
- 35 described further below. Many plants used in traditional medicine as treatment or prophylaxis for diarrhea have been found to contain tannins and proanthocyanidins in particular

WO 98/16111

PCT/US97/18845

(see, e.g., Yoshida et al., 1993, *Phytochemistry* 32:1033; Yoshida et al., 1992, *Chem. Pharm. Bull.*, 40:1997; Tamaka et al., 1992, *Chem. Pharm. Bull.* 40:2092). Crude extracts from medicinal plants, for example, *Pycanthus angolensis* and *Baphia*
5 *nitida*, have been shown to have antidiarrheal qualities in animal tests (Onwukaeme and Anuforo, 1993, *Discovery and Innovation*, 5:317; Onwukaeme and Lot, 1991, *Phytotherapy Res.*, 5:254). Crude extracts which contain tannins, in particular extracts from carob pods and sweet chestnut wood,
10 have been proposed as treatments or prophylactics for diarrhea (U.S. Patent No. 5,043,160; European Patent No. 481,396).

Crude plant extracts containing proanthocyanidins have also been proposed as treatments or prophylactics for
15 diarrhea. For example, crude fruit skin extracts, which contain anthocyanidins as well as other compounds, have been suggested for use against diarrhea (U.S. Patent No. 4,857,327). The bark from the *Q. petrea* tree, traditionally used against diarrhea, has been shown to contain oligomeric
20 proanthocyanidins (Konig and Scholz, 1994, *J. Nat. Prod.*, 57:1411; Pallenbach, 1993, *Planta Med.*, 59:264). A fraction of *Sclerocarya birrea* bark extract, which also contains procyanidins, reduced the intestinal contractions associated with experimentally-induced diarrhea (Galvez et al., 1993,
25 *Phyt. Res.*, 7:25; Galvez et al., 1991, *Phyt. Res.*, 5:276). However, none of these studies demonstrate that the proanthocyanidins are specifically responsible for the antidiarrheal activity of the extracts.

Other studies suggest that certain preparations
30 containing proanthocyanidins may interfere with cholera toxin action in the gut. Crude tea extract, which contains catechins (proanthocyanidin monomers), has been demonstrated to prevent both cholera toxin-induced morphological changes in cultured CHO cells and cholera toxin-induced intestinal
35 fluid accumulation in mice when administered five minutes after the cholera toxin (Toda et al., 1991, *J. App. Bact.*, 70:109). However, the crude tea extract could not prevent

WO 98/16111

PCT/US97/18845

the fluid accumulation in the mouse intestine when administered thirty minutes after the cholera toxin, and the catechins were not shown to be the active agent in the extract. Furthermore, a fraction of *Guazuma ulmifolia* bark
5 extract containing proanthocyanidins reduced cholera toxin-induced ion efflux in isolated rabbit intestinal tissue, apparently through a physical interaction of the polymeric proanthocyanidins with the cholera toxin as determined by SDS-PAGE analysis (Hor et al., 1996, *Phytochemistry* 42:109;
10 Hor et al., 1995, *Planta Med.*, 61:208). Addition of the fraction after addition of the cholera toxin, however, had no effect on chloride ion secretion. Thus, completely contrary to the present invention, this fraction would not be effective to reduce or prevent the fluid loss after exposure
15 to the agent causing the secretory diarrhea and therefore would not be useful as a therapeutic for secretory diarrhea.

Proanthocyanidins have different physiological effects, depending on their structure and source. Other proanthocyanidins are actually contraindicated for treatment
20 or prevention of diarrhea. Oligomeric proanthocyanidins isolated from black bean were shown to increase chloride secretion and reduce sodium resorption in isolated intestinal tissue [Silverstein, 1989, "Procyanidin from Black Bean (Phaseolus Vulgaris): Effects on Transport of Sodium,
25 Chloride, Glucose, and Alanine in the Rat Ileum," Washington State University (Dissertation)]. The increased ion concentration in the intestine would thus promote fluid accumulation in the intestinal lumen and aggravate the fluid and electrolyte loss and dehydration associated with
30 secretory diarrhea. In fact, the reference specifically teaches away from the use of proanthocyanidins as a treatment for diarrhea and suggests that the proanthocyanidins might cause secretory diarrhea.


35

2.3. PROANTHOCYANIDINS

Proanthocyanidin and proanthocyanidin polymers are phenolic substances found in a wide variety of plants,

PCT/US97/18845


20



35

WO 98/16111

PCT/US97/18845



The monomer unit (generally termed "leucoanthocyanidin") of the polymer chain may be based on either of two stereochemistries of the C-ring, at a 2 and/or 4 position designated cis (called epicatechins) or trans (called catechin). Therefore, the polymer chains are based on different structural units, which create a wide variation of polymeric proanthocyanidins and a large number of possible isomers (Hemingway et al., 1982, *J.C.S. Perkin*, 1:1217). ¹³C NMR has been useful to identify the structures of polymeric proanthocyanidins and recent work has elucidated the chemistry of di-, tri- and tetra-meric proanthocyanidins. Larger polymers of the flavonoid 3-ol units are predominant in most plants, and are found with average molecular weights above 2,000 daltons, containing 6 or more units (Newman et al., 1987, *Mag. Res. Chem.*, 25:118).

2.4. ETHNOBOTANICAL USES OF EXTRACTS AND COMPOUNDS FROM CROTON AND CALOPHYLLUM SPECIES

A number of different Croton tree species, including *Croton sakutaris*, *Croton gossypifolius*, *Croton palanostima*, *Croton lechleri*, *Croton erythrochilus* and *Croton draconoides*,

WO 98/16111

PCT/US97/18845

found in South America, produce a red viscous latex sap called Sangre de Drago or "Dragon's Blood". Sangre de Drago is most often utilized by mixed descent and native people of the Peruvian Amazon for flu and diarrhea. It is taken
5 internally for tonsillitis, throat infections, tuberculosis, peptic ulcers, intestinal disorders, rheumatism and to enhance fertility and is used by both adults and children. It is also used extensively to stop bleeding, for herpes virus lesions, and for wound healing. The sap is placed
10 directly on open wounds as an anti-infective and to accelerate the healing process. It is also utilized as a vaginal wash in cases of excessive bleeding.

It has been shown that Sangre de Drago from *Croton draconoides* and from *Croton lechleri* contains an alkaloid
15 identified as taspine, which exhibits anti-inflammatory activity (Persinos et al., 1979, *J. Pharm. Sci.*, 68:124). Taspine has also been shown to inhibit RNA-directed DNA polymerase activity in the avian myeloblastosis virus, Rauscher leukemia virus and Simian sarcoma virus (Sethi,
20 1977, *Canadian J. Pharm. Sci.*, 12:7).

A variety of phenolic and diterpene compounds isolated from Sangre de Drago were tested for their antitumor, antibacterial and wound healing properties (Chen et al., *Planta Med.*, 60:541). The proanthocyanidins in the sap were
25 found to have little antitumor or antibacterial activity and slight wound healing activity.

U.S. Patent No. 5,211,944 first described the isolation of a proanthocyanidin polymer composition from *Croton* spp. and the use of the composition as an antiviral
30 agent (See also Ubillas et al., 1994, *Phytomedicine*, 1:77). The proanthocyanidin polymer composition was shown to have antiviral activity against a variety of viruses including, respiratory syncytial, influenza, parainfluenza and herpes viruses.

35 *Calophyllum inophyllum* is a tree ranging from India to East Africa to Polynesia. Seed oil is used in folk medicine as an antiparasitic in treatment of scabies, ringworm and

WO 98/16111

PCT/US97/18845

dermatosis as well as other uses such as analgesia. In Indo-China, the powdered resin is used for ulcers and wound healing. In Indonesia, the bark is applied externally to treat swollen glands and internally as a diuretic. The sap
5 is used as an emollient for chest pain as well as for tumors and swelling. Leaf extracts are used as a wash for inflamed eyes. The Cambodians use leaf extracts in inhalations for treatment of vertigo and migraine. The Samoans use the sap as an arrow poison.

10 U.S. Patent No. 5,211,944 also discloses the isolation of a proanthocyanidin polymer composition from *Calophyllum inophyllum* and the use of this composition as an antiviral agent.

It has been determined that the proanthocyanidin polymer
15 compositions of the invention are acid labile and subject to inactivation by the acidic environment of the stomach. Before the present application, no disclosure has been made of a pharmaceutical composition of a proanthocyanidin polymer composition isolated from either *Croton* spp. or *Calophyllum*
20 spp. which protects the proanthocyanidin polymer composition from the acidity of gastric fluid so that the proanthocyanidin polymer composition can be administered orally for treatment of secretory diarrhea.

The need remains for an effective pharmaceutical
25 composition, the administration of which will reduce the ion efflux into the gut elicited by secretory diarrhea. Such an agent would be useful to prevent the fluid and electrolyte loss and dehydration caused by secretory diarrhea. The object of the present invention is to provide an effective
30 pharmaceutical formulation of an antidiarrheal agent which will fulfill this need, and specifically to provide a pharmaceutical formulation which will protect the antidiarrheal agent from the acidity of the stomach as well as methods for treating diarrhea using the pharmaceutical
35 formulation.

WO 98/16111

PCT/US97/18845

3. SUMMARY OF THE INVENTION

The present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of an antidiarrheal agent comprising a proanthocyanidin polymer composition. The proanthocyanidin polymer composition is preferably prepared from a *Croton* spp, preferably *Croton lechleri*. The proanthocyanidin polymer composition can also be prepared from a *Calophyllum* spp., in particular *Calophyllum inophyllum*.

The pharmaceutical compositions of the invention are formulated to protect the proanthocyanidin polymeric composition from degradation by the acidic conditions of the stomach. In a preferred embodiment, the proanthocyanidin composition is enteric coated. In another preferred embodiment, the proanthocyanidin polymer composition is provided in combination with a substance able to reduce the secretion of stomach acid or able to reduce the acidity of stomach fluid.

The present invention also encompasses methods for treating diarrhea, particularly secretory diarrhea, in warm blooded animals, including humans, comprising administering, to a non-human animal or human suffering from diarrhea, a pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin polymer composition isolated from a *Croton* spp. or a *Calophyllum* spp. or a pharmaceutically acceptable derivative thereof formulated to protect the proanthocyanidin polymer composition from the action of stomach acid, and a pharmaceutically acceptable carrier. In addition, the present invention encompasses methods for treating secretory diarrhea in animals, including humans, comprising administering, to a non-human animal or human suffering from diarrhea, (a) a pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin polymer composition isolated from a *Croton* spp. or a *Calophyllum* spp. or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier; and (b) a pharmaceutical composition either

WO 98/16111

PCT/US97/18845

comprising an amount effective to inhibit stomach acid secretion of a compound that is effective to inhibit stomach acid secretion or comprising an amount effective to neutralize stomach acid of a compound that is effective to
5 neutralize stomach acid, and a pharmaceutically acceptable carrier.

The present invention also provides methods for preventing diarrhea in warm blooded animals, including humans, comprising administering, to a non-human animal or
10 human at risk of developing diarrhea, a pharmaceutical composition comprising a prophylactically effective amount of a proanthocyanidin polymer composition isolated from a *Croton* spp. or a *Calophyllum* spp. or a pharmaceutically acceptable derivative thereof formulated to protect the proanthocyanidin
15 polymer composition from the action of stomach acid, and a pharmaceutically acceptable carrier.

4. BRIEF DESCRIPTION OF THE FIGURES

Figure 1. An overlay of HPLC chromatograms showing the
20 chromatographic profiles of the proanthocyanidin polymer composition from *C. lechleri* after different treatments as UV absorption in milliabsorption units (mAU) over time of chromatography in minutes. The chromatogram graphed as a dotted line depicts the profile of the proanthocyanidin
25 polymer composition after incubation in water ("in water"), the solid line depicts the proanthocyanidin polymer composition profile after incubation in HCl for 0.03 hours ("HCl after 0.03 h"), and the dashed line depicts the proanthocyanidin polymer composition from *C. lechleri* profile
30 after incubation in HCl for 2.0 hours ("HCl after 2.0 h").

Figure 2. A sample HPLC chromatogram of the proanthocyanidin polymer composition from *C. lechleri* after incubation in simulated gastric fluid at 37°C for 0.03 hours. The chromatogram is graphed as UV absorption (mAU) over time
35 in minutes.

Figure 3. A sample HPLC chromatogram of the proanthocyanidin polymer composition from *C. lechleri* after

WO 98/16111

PCT/US97/18845

incubation in simulated gastric fluid at 37°C for 2 hours. The chromatogram is graphed as UV absorption (mAU) over time in minutes.

Figure 4. A sample HPLC chromatogram of the
5 proanthocyanidin polymer composition from *C. lechleri* after incubation in simulated gastric fluid at 37°C for 2 hours, and followed by incubation for 4 more hours after dilution 1:1 in simulated intestinal fluid. The chromatogram is graphed as UV absorption (mAU) over time in minutes.

10 Figure 5. A sample HPLC chromatogram of the proanthocyanidin polymer composition from *C. lechleri* after incubation in simulated gastric fluid at 37°C for 2 hours, and followed by incubation for 6 more hours after dilution 1:1 in simulated intestinal fluid. The chromatogram is
15 graphed as UV absorption (mAU) over time in minutes.

Figure 6. Plot of the percentage of peak area ("% Peak Area"), as calculated by dividing peak area of the HPLC profile of the proanthocyanidin polymer composition from *C. lechleri* in the test-medium by the peak area of the HPLC
20 profile of the proanthocyanidin polymer composition in water and multiplying by 100, as a function of incubation time in hours. The line with open squares represents the % peak area of the proanthocyanidin polymer composition after incubation in SGF (simulated gastric fluid). The dotted line with
25 diamonds represents the % peak area of the proanthocyanidin polymer composition after 2 hours of incubation in SGF and then dilution 1:1 into SIF (simulated intestinal fluid) for further incubation.

Figure 7. This bar graph depicts the effect of the
30 enteric coated formulation of the proanthocyanidin polymer composition from *C. lechleri* on intestinal fluid accumulation in mice exposed to cholera toxin. Results are presented as an average, for each group of mice A-C, of the fluid accumulation ratio in mg fluid/mg intestine. Mice in group A
35 were treated only with water; mice in group B were treated with 131 mg enteric coated proanthocyanidin polymer composition in guar gum/kg; mice in group C were administered

WO 98/16111

PCT/US97/18845

"EUDRAGIT™" and sugar with guar gum. The mice in all groups were evaluated at 7 hours after exposure to the cholera toxin. See Section 7, *infra* for details.

Figure 8. This bar graph depicts the effect of the enteric coated formulation of the proanthocyanidin polymer composition from *C. lechleri* on intestinal fluid accumulation in mice exposed to cholera toxin. Results are presented as an average, for groups of mice A and B, of the fluid accumulation ratio in mg fluid/mg intestine. Mice in group A were treated with "EUDRAGIT™" and sugar in water, and mice in group B were treated with 131 mg enteric coated proanthocyanidin polymer composition/kg.

5. DETAILED DESCRIPTION OF THE INVENTION

5.1. PREPARATION OF THE PROANTHOCYANIDIN POLYMER COMPOSITION

The proanthocyanidin polymer composition, effective for treatment of diarrhea, is comprised of monomeric units of leucoanthocyanidins. Leucoanthocyanidins are generally monomeric flavonoids which include catechins, epicatechins, gallo catechins, galloepicatechins, flavanols, flavonols, and flavan-3,4-diols, leucocyanidins and anthocyanidins. The proanthocyanidin polymer composition useful for treating secretory diarrhea is comprised of polymers of 2 to 30 flavonoid units, preferably 2 to 15 flavonoid units, more preferably 2 to 11 flavonoid units and most preferably an average of 7 flavonoid units with an average molecular weight of 2100 daltons.

The proanthocyanidin polymer composition used in the present invention is preferably isolated from a *Croton* spp. or *Calophyllum* spp. by the method disclosed in U.S. Patent No. 5,211,944, which is incorporated herein by reference.

In a preferred embodiment, the proanthocyanidin polymer composition is isolated from *Croton lechleri*. In another embodiment, the proanthocyanidin polymer composition is isolated from *Calophyllum inophyllum*.

WO 98/16111

PCT/US97/18845

5.2 PHARMACEUTICAL FORMULATIONS

The proanthocyanidin polymer composition has been shown to be labile in the acid environment of the stomach and has been found to be stable at pH 5.0 to approximately pH 8.0 (see Section 6, *infra*). Thus, the invention provides pharmaceutical formulations of proanthocyanidin polymer compositions which protect the compositions from the acidity of gastric secretions. In a preferred embodiment, the pharmaceutical formulations of the invention contain the proanthocyanidin polymer composition with an enteric coating along with another pharmaceutically acceptable vehicle. In another embodiment, the pharmaceutical compositions containing the proanthocyanidin polymer composition alternatively include one or more substances which either neutralize stomach acid or are active to prevent secretion of stomach acid. These formulations can be prepared by methods known in the art, see, e.g., methods described in Remington's Pharmaceutical Sciences, 18th Ed., ed. Alfonso R. Gennaro, Mack Publishing Co., Easton, PA, 1990.

The proanthocyanidin polymer composition can be provided in any therapeutically acceptable pharmaceutical form. The pharmaceutical composition can be formulated for oral administration as, for example but not limited to, drug powders, crystals, granules, small particles (which include particles sized on the order of micrometers, such as microspheres and microcapsules), particles (which include particles sized on the order of millimeters), beads, microbeads, pellets, pills, microtablets, compressed tablets or tablet triturates, molded tablets or tablet triturates, and in capsules, which are either hard or soft and contain the composition as a powder, particle, bead, solution or suspension. The pharmaceutical composition can also be formulated for oral administration as a solution or suspension in an aqueous liquid, as a liquid incorporated into a gel capsule or as any other convenient formulation for administration, or for rectal administration, as a suppository, enema or other convenient form. The

WO 98/16111

PCT/US97/18845

proanthocyanidin polymeric composition can also be provided as a controlled release system (see, e.g., Langer, 1990, Science 249: 1527-1533.

The pharmaceutical formulation can also include any type
5 of pharmaceutically acceptable excipients, additives or vehicles. For example, but not by way of limitation, diluents or fillers, such as dicalcium phosphate, calcium sulfate, lactose, cellulose, kaolin, mannitol, sodium chloride, dry starch, sorbitol, sucrose, inositol, powdered
10 sugar, bentonite, microcrystalline cellulose, or hydroxypropylmethylcellulose may be added to the proanthocyanidin polymer composition to increase the bulk of the composition. Also, binders, such as but not limited to, starch, gelatin, sucrose, glucose, dextrose, molasses,
15 lactose, acacia gum, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone, Veegum and larch arabogalactan, polyethylene glycol, ethylcellulose, and waxes, may be added
20 to the formulation to increase its cohesive qualities. Additionally, lubricants, such as but not limited to, talc, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, carbowax,
25 sodium lauryl sulfate, and magnesium lauryl sulfate may be added to the formulation. Also, glidants, such as but not limited to, colloidal silicon dioxide or talc may be added to improve the flow characteristics of a powdered formulation. Finally, disintegrants, such as but not limited to, starches,
30 clays, celluloses, algins, gums, crosslinked polymers (e.g., croscarmellose, crospovidone, and sodium starch glycolate), Veegum, methylcellulose, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp, carboxymethylcellulose, or
35 sodium lauryl sulfate with starch may also be added to facilitate disintegration of the formulation in the intestine.

WO 98/16111

PCT/US97/18845

In a preferred embodiment of the invention, the proanthocyanidin polymer composition is formulated with a substance that protects the proanthocyanidin polymer composition from the stomach acid. In a more preferred
5 embodiment, the proanthocyanidin composition is enteric coated. Enteric coatings are those which remain intact in the stomach, but will dissolve and release the contents of the dosage form once it reaches the small intestine. A large number of enteric coatings are prepared with ingredients that
10 have acidic groups such that at the very low pH present in the stomach, i.e. pH 1.5 to 2.5, the acidic groups are not ionized and the coating remains in an undissociated, insoluble form. At higher pH levels, such as in the environment of the intestine, the enteric coating is
15 converted to an ionized form, which can be dissolved to release the proanthocyanidin composition. Other enteric coatings remain intact until they are degraded by enzymes in the small intestine, and others break apart after a defined exposure to moisture, such that the coatings remain intact
20 until after passage into the small intestines.

Polymers which are useful for the preparation of enteric coatings include, but are not limited to, shellac, starch and amylose acetate phthalates, styrene-maleic acid copolymers, cellulose acetate succinate, cellulose acetate phthalate
25 (CAP), polyvinylacetate phthalate (PVAP), hydroxypropylmethylcellulose phthalate (grades HP-50 and HP-55), ethylcellulose, fats, butyl stearate, and methacrylic acid-methacrylic acid ester copolymers with acid ionizable groups ("EUDRAGIT™"), such as "EUDRAGIT™ L 30D", "EUDRAGIT™
30 RL 30D", "EUDRAGIT™ RS 30D" and EUDRAGIT™ L 100-55". In a preferred embodiment, the pharmaceutical composition contains a proanthocyanidin polymeric composition and the enteric coating polymer "EUDRAGIT™ L 30D", an anionic copolymer of methacrylic acid and methyl acrylate with a mean molecular
35 weight of 250,000 Daltons.

The disintegration of the enteric coating occurs either by hydrolysis by intestinal enzymes or by emulsification and

WO 98/16111

PCT/US97/18845

dispersion by bile salts, depending upon the type of coating used. For example, esterases hydrolyze esterbutyl stearate to butanol and stearic acid and, as the butanol dissolves, the stearic acid flakes off of the medicament. Additionally, 5 bile salts emulsify and disperse ethylcellulose, hydroxypropylmethylcellulose, fats and fatty derivatives. Other types of coatings are removed depending on the time of contact with moisture, for example coatings prepared from powdered carnauba wax, stearic acid, and vegetable fibers of 10 agar and elm bark rupture after the vegetable fibers absorb moisture and swell. The time required for disintegration depends upon the thickness of the coating and the ratio of vegetable fibers to wax.

Application of the enteric coating to the 15 proanthocyanidin polymer composition can be accomplished by any method known in the art for applying enteric coatings. For example, but not by way of limitation, the enteric polymers can be applied using organic solvent based solutions containing from 5 to 10% w/w polymer for spray applications 20 and up to 30% w/w polymer for pan coatings. Solvents that are commonly in use include, but are not limited to, acetone, acetone/ethyl acetate mixtures, methylene chloride/methanol mixtures, and tertiary mixtures containing these solvents. Some enteric polymers, such as methacrylic acid-methacrylic 25 acid ester copolymers ("EUDRAGIT™") can be applied using water as a solvent. The volatility of the solvent system must be tailored to prevent sticking due to tackiness and to prevent high porosity of the coating due to premature spray drying or precipitation of the polymer as the solvent 30 evaporates.

Furthermore, plasticizers can be added to the enteric coating to prevent cracking of the coating film. Suitable plasticizers include the low molecular weight phthalate esters, such as diethyl phthalate, acetylated monoglycerides, 35 triethyl citrate/polyethyl glycoltributyl citrate and triacetin. Generally, plasticizers are added at a concentration of 10% by weight of enteric coating polymer

WO 98/16111

PCT/US97/18845

weight. Other additives such as emulsifiers, for example detergents and simethicone, and powders, for example talc, may be added to the coating to improve the strength and smoothness of the coating. Additionally, pigments may be
5 added to the coating to add color to the pharmaceutical formulation.

In a preferred embodiment, the pharmaceutical composition of the proanthocyanidin polymer composition is provided as enteric coated beads in hard-shell gelatin
10 capsules. The proanthocyanidin polymer beads are prepared by mixing a proanthocyanidin polymer composition with hydroxypropylmethylcellulose and layering the mixture onto nonpareil seeds (sugar spheres). The beads are then covered with a seal coat of Opadry Clear (mixed with water). A
15 preferred enteric coating for the proanthocyanidin polymer composition is "EUDRAGIT" L 30D" applied as an aqueous dispersion containing 30% w/w dry polymer substance, which is supplied with 0.7% sodium lauryl sulfate NF (SLS) and 2.3% polysorbate 80 NF (Tween 20) as emulsifiers, to which the
20 plasticizers, polyethylene glycol and citric acid esters, are added to improve the elasticity of the coating, and talc is added to reduce the tendency of the enteric coating polymer to agglutinate during the application process and to increase the smoothness of the film coating. The final composition of
25 the enteric coated beads is 17.3% w/w nonpareil seeds, 64.5% w/w proanthocyanidin polymer composition, 1.5% w/w hydroxypropylmethylcellulose, 0.5% w/w Opadry clear, 14.5% w/w "EUDRAGIT" L 30D", 1.45% w/w triethyl citrate, and 0.25% w/w glyceryl monostearate. This pharmaceutical formulation
30 may be prepared by any method known in the art or the method described in section 8.1, *infra*.

In another preferred embodiment, the pharmaceutical composition of the proanthocyanidin polymer composition is formulated as enteric coated granules or powder (microspheres
35 with a diameter of 300-500 μ) provided in either hard shell gelatin capsules or suspended in an oral solution for pediatric administration. The enteric coated

WO 98/16111

PCT/US97/18845

proanthocyanidin polymer composition powder or granules may also be mixed with food, particularly for pediatric administration. This preparation may be prepared using techniques well known in the art, such as the method
5 described in Section 8.2, *infra*. In general, the proanthocyanidin polymer composition granules and powder can be prepared using any method known in the art, such as but not limited to, crystallization, spray-drying or any method of comminution, preferably using a high speed
10 mixer/granulator. Examples of high speed mixer/granulators include the "LITTLEFORD LODIGE™" mixer, the "LITTLEFORD LODIGE™" MGT mixer/granulator, and the "GRAL™" mixer/granulator. During the high-shear powder mixing, solutions of granulating agents, called binders, are sprayed
15 onto the powder to cause the powder particles to agglomerate, thus forming larger particles or granules. Granulating agents which are useful for preparing the proanthocyanidin polymer composition granules, include but are not limited to, cellulose derivatives (including carboxymethylcellulose,
20 methylcellulose, and ethylcellulose), gelatin, glucose, polyvinylpyrrolidone (PVP), starch paste, sorbitol, sucrose, dextrose, molasses, lactose, acacia gum, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, Veegum and larch arabogalactan, polyethylene
25 glycol, and waxes. Granulating agents may be added in concentrations ranging from 1 to 30% of the mass of the particles or granules.

The proanthocyanidin polymer composition powder or granules are preferably coated using the fluidized bed
30 equipment. The granules or powder are then covered with a seal coat of Opadry Clear (mixed with water). A preferred enteric coating for the proanthocyanidin polymer composition is "EUDRAGIT™ L 30D" applied as an aqueous dispersion containing 30% w/w dry polymer substance, which is supplied
35 with 0.7% sodium lauryl sulfate NF (SLS) and 2.3% polysorbate 80 NF (Tween 20) as emulsifiers, to which the plasticizers, polyethylene glycol and citric acid esters, are added to

WO 98/16111

PCT/US97/18845

improve the elasticity of the coating, and talc is added to reduce the tendency of the enteric coating polymer to agglutinate during the application process and to increase the smoothness of the film coating. The final composition of the enteric coated powder is 81.8% w/w proanthocyanidin polymer composition, 1.5% w/w hydroxypropylmethylcellulose, 0.5% w/w Opadry clear, 14.5% w/w "EUDRAGIT" L 30D", 1.45% w/w triethyl citrate, and 0.25% w/w glyceryl monostearate. The final composition of the enteric coated granules is 81.8% w/w proanthocyanidin polymer composition, 10% polyvinylpyrrolidone, 1.5% w/w hydroxypropylmethylcellulose, 0.5% w/w Opadry clear, 14.5% w/w "EUDRAGIT" L 30D", 1.45% w/w triethyl citrate, and 0.25% w/w glyceryl monostearate.

The enteric coated proanthocyanidin polymer composition granules or powder particles can further be suspended in a solution for oral administration, particularly for pediatric administration. The suspension can be prepared from aqueous solutions to which thickeners and protective colloids are added to increase the viscosity of the solution to prevent rapid sedimentation of the coated powder particles or granules. Any material which increases the strength of the hydration layer formed around suspended particles through molecular interactions and which is pharmaceutically compatible with the proanthocyanidin polymer composition can be used as a thickener, such as but not limited to, gelatin, natural gums (e.g., tragacanth, xanthan, guar, acacia, panwar, ghatti, etc.), and cellulose derivatives (e.g., sodium carboxymethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose, etc.). Optionally, a surfactant such as Tween may be added to improve the action of the thickening agent. A preferred suspension solution is a 2% w/w hydroxypropylmethylcellulose solution in water containing 0.2% Tween.

In yet another embodiment, the proanthocyanidin polymer composition is formulated as enteric coated tablets. In this embodiment, the proanthocyanidin polymer composition is granulated with any pharmaceutically acceptable diluent (such

WO 98/16111

PCT/US97/18845

as those listed above) by the methods described above for preparing the proanthocyanidin polymer composition granules. Then, the granules are compressed into tablets using any method well known in the art, for example but not limited to, 5 the wet granulation method, the dry granulation method or the direct compression method. A preferred diluent is microcrystalline cellulose ("AVICEL"™ PH 200/300"). Additionally, disintegrants, such as those described above, and lubricants, such those described above, may also be added 10 to the tablet formulation. A preferred tablet formulation contains 250 mg proanthocyanidin polymer composition, 7 mg of the disintegrant "AC-DI-SOL"™ (cross linked sodium carboxymethylcellulose), 1.75 mg of the lubricant magnesium stearate and the weight of "AVICEL"™ PH 200/300" necessary to 15 bring the mixture up to 350 mg. The tablets are coated with an enteric coating mixture prepared from 250 grams "EUDRAGIT"™ L 30 D-55", 7.5 grams triethyl citrate, 37.5 grams talc and 205 grams water. This formulation may be prepared by any method well known in the art or by the method described in 20 Section 8.3, *infra*.

The proanthocyanidin polymer composition formed into small particles (which include particles sized on the order of micrometers, such as microspheres and microcapsules), particles (which include particles sized on the order of 25 millimeters), drug crystals, pellets, pills and microbeads can be coated using a fluidized-bed process. This process uses fluidized-bed equipment, such as that supplied by "GLATT"™, "AEROMATIC"™, "WURSTER"™, or others, by which the proanthocyanidin polymer composition cores are whirled up in 30 a closed cylindrical vessel by a stream of air, introduced from below, and the enteric coat is formed by spray drying it onto the cores during the fluidization time. To coat tablets or capsules, an Accela-Cota process ("MANESTY"™) can be used. By this process, the tablets or capsules are placed in a 35 rotating cylindrical coating pan with a perforated jacket and spraying units are installed within the pan and the dry air is drawn in through the rotating tablets or capsules. Any

WO 98/16111

PCT/US97/18845

other type of coating pan, such as the "GLATT™" immersion sword process, the "DRIAM™" Dricoater, "STEINBERG™" equipment, "PELLEGRINI™" equipment, or "WALTHER™" equipment can also be used.

5 In another preferred embodiment, the proanthocyanidin polymer composition is provided as a suppository for rectal administration. Suppositories can be formulated with any base substance which is pharmaceutically acceptable for the preparation of suppositories and which is compatible with the
10 proanthocyanidin polymer composition. Because rectal administration does not expose the proanthocyanidin polymer composition to the acid environment of the stomach, the pharmaceutical formulations for rectal administration need not be formulated to protect the composition from acid
15 conditions. Suppository bases which may be used to prepare suppositories with the proanthocyanidin polymer composition include, but are not limited to, cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols or fatty acids of polyethylene glycols
20 or glycol-surfactant combinations or nonionic surfactant materials (such as polyoxyethylene sorbitan fatty acid esters (Tweens), polyoxyethylene stearates, and mixtures of sorbitan fatty acid esters (Span and Arlacel)). However, because of the hydrophilic nature of the proanthocyanidin polymer
25 composition, a hydrophilic base for the suppository is suggested. A preferred suppository formulation for the proanthocyanidin polymer composition is prepared from 91 grams glycerin, 9 grams sodium stearate, 5 grams purified water and can be 5% to 50% w/w proanthocyanidin polymer
30 composition. Alternatively, the suppository may contain 10 grams proanthocyanidin polymer composition, 20 grams gelatin, and 70 grams of glycerin. Suppositories prepared from the proanthocyanidin polymer composition can be shaped by any method known in the art, including but not limited to,
35 compression molding, fusion, or, preferably, melt molding. A method for preparing suppositories from the proanthocyanidin polymer composition is described in Section 8.4, *infra*.

WO 98/16111

PCT/US97/18845

In another embodiment, the proanthocyanidin polymer composition is formulated with a compound or compounds which neutralize stomach acid. Alternatively, the pharmaceutical composition containing the proanthocyanidin polymer composition is administered either concurrent with or subsequent to administration of a pharmaceutical composition which neutralize stomach acid. Compounds, such as antacids, which are useful for neutralizing stomach acid include, but are not limited to, aluminum carbonate, aluminum hydroxide, bismuth subnitrate, bismuth subsalicylate, calcium carbonate, dihydroxyaluminum sodium carbonate, magaldrate, magnesium carbonate, magnesium hydroxide, magnesium oxide, and mixtures thereof.

In another embodiment, the proanthocyanidin polymer composition is formulated with a compound or compounds which inhibit the secretion of stomach acid. Alternatively, the pharmaceutical composition containing the proanthocyanidin polymer composition is administered either concurrent with or subsequent to administration of a pharmaceutical composition active to inhibit the secretion of stomach acid. Compounds which are useful for inhibiting the secretion of stomach acid include, but are not limited to, ranitidine, nizatidine, famotidine, cimetidine, and misoprostol.

5.3 APPLICATIONS OR METHODS OF USE

The proanthocyanidin polymer composition reduces chloride flux across intestinal epithelial cells and reduces fluid movement into the intestinal lumen which results in fluid loss and dehydration associated with secretory diarrhea. Thus, the pharmaceutical formulations and methods of the invention are useful in prophylactic and therapeutic applications against secretory diarrhea, particularly in preventing the dehydration and electrolyte loss that accompanies secretory diarrhea.

The pharmaceutical formulations of the proanthocyanidin polymer composition can be used therapeutically or prophylactically against any type of secretory diarrhea in

WO 98/16111

PCT/US97/18845

either humans or animals. In a preferred embodiment, the pharmaceutical formulation is used to treat secretory diarrheas caused by enteric bacteria. These enteric bacteria include, but are not limited to, *Vibrio cholerae*, *E. coli*,
5 including the enteropathogenic, enterotoxigenic, enteroadherent, enterohemorrhagic, or enteroinvasive types of *E. coli*, other *Vibrio* spp., *Campylobacter* spp., *Salmonella* spp., *Aeromonas* spp., *Plesiomonas* spp., *Shigella* spp., *Klebsiella* spp., *Citrobacter* spp., *Yersinia* spp., *Clostridium*
10 spp., *Bacteriodes* spp., *Staphylococcus* spp., and *Bacillus* spp. This embodiment also includes the treatment of traveler's diarrhea.

In another embodiment, the pharmaceutical formulation is used to treat secretory diarrhea caused by protozoa,
15 including but not limited to, *Giardia* and *Cryptosporidium* spp., particularly *Cryptosporidium parvum*.

In another embodiment, the pharmaceutical formulation is used to treat secretory diarrhea caused by non-infectious etiologies, such as but not limited to, non-specific
20 diarrhea, inflammatory bowel syndrome, ulcerative colitis, and cancers and neoplasias of the gastrointestinal tract.

In another embodiment, the pharmaceutical formulations of the invention are used for the treatment of HIV-Associated Chronic Diarrhea in patients with AIDS. In yet another
25 embodiment, the pharmaceutical formulation is used to treat diarrhea in infants or children, including but not limited to, diarrhea caused by rotavirus.

The pharmaceutical formulations of the invention can also be used to treat diarrhea in non-human animals,
30 particularly in farm animals, such as but not limited to, bovine animals, swine, ovine animals, poultry (such as chickens), and equine animals, and other domesticated animals such as canine animals and feline animals. In particular the pharmaceutical formulations of the invention can be used to
35 treat diarrheal disease in non-human animals, particularly food animals such as cattle, sheep and swine, caused by bacterial pathogens such as enterotoxigenic,

WO 98/16111

PCT/US97/18845

enterohemorrhagic and other *E. coli*, *Salmonella* spp., *Clostridium perfringens*, *Bacteriodes fragilis*, *Campylobacter* spp., and *Yersinia enterocolitica*, protozoal pathogens, particularly *Cryptosporidium parvum*, and viral agents, particularly rotaviruses and coronaviruses, but also togavirus, parvovirus, calicivirus, adenoviruses, bredaviruses, and astroviruses.

Additionally, the pharmaceutical formulations of the invention may also be administered prophylactically to humans and non-human animals to prevent the development of secretory diarrhea. By way of example, but not by way of limitation, a proanthocyanidin polymer composition pharmaceutical formulation can be administered to tourists traveling to a country where there is a risk of travelers diarrhea at a time or times that are effective for preventing the disease. The pharmaceutical compositions of the invention can be administered to AIDS patients to prevent the occurrence of HIV-Associated Chronic Diarrhea. Also, the pharmaceutical compositions of the invention can be administered to children in a community threatened with cholera epidemic or rotavirus epidemic to prevent the spread of the disease. Likewise, the pharmaceutical compositions of the invention can be administered to farm animals, particularly young or recently weaned farm animals, to prevent the development of diarrheal disease.

When used according to the formulations and methods of the present invention as a treatment for secretory diarrhea, effective dosage ranges of the pharmaceutical formulations of the proanthocyanidin polymer composition for oral administration are in the range of 0.1 to 100 mg/kg per day, preferably about 0.1 to about 40 mg/kg per day, optionally 0.1 to 25 mg/kg per day, and also optionally 0.1 to 10 mg/kg per day. It should be appreciated that the appropriate dose will depend upon the type and severity of the secretory diarrhea. It has been found that human subjects can tolerate at least up to 2 grams of the proanthocyanidin polymer composition per day (25-30 mg/kg/day) for up to 2 days. It

WO 98/16111

PCT/US97/18845

is believed that doses may exceed 40 mg/kg per day, optionally up to 100 mg/kg per day, if such dosages are necessary to treat the secretory diarrhea.

When used according to the formulations and methods of the present invention as a prophylaxis for secretory diarrhea, effective dosage ranges of the pharmaceutical formulations of the proanthocyanidin polymer composition for oral administration are in the range of 0.1 to 100 mg/kg per day, preferably about 0.1 to about 40 mg/kg per day, optionally 0.1 to 25 mg/kg per day, and also optionally 0.1 to 10 mg/kg per day. It should be appreciated that the appropriate dose will depend upon the type and severity of the secretory diarrhea to be prevented. It has been found that human subjects can tolerate at least up to 2 grams of the proanthocyanidin polymer composition per day (25-30 mg/kg/day) for up to 2 days. It is believed that doses may exceed 40 mg/kg per day, optionally up to 100 mg/kg per day, if such dosages are necessary to prevent the secretory diarrhea.

The proanthocyanidin polymer composition can be administered for treatment or prevention of secretory diarrhea in any therapeutically acceptable pharmaceutical form. The pharmaceutical composition can be administered orally, in the form of, such as but not limited to, drug crystals, granules, small particles (which include particles sized on the order of micrometers, such as microspheres and microcapsules), particles (which include particles sized on the order of millimeters) beads, microbeads, pellets, pills, microtablets, compressed tablets or tablet triturates, molded tablets or tablet triturates, and in capsules, which are either hard or soft and contain the composition as a powder, particle, bead, solution or suspension. The pharmaceutical composition can also be administered orally, as a solution or suspension in an aqueous liquid, as a liquid incorporated into a gel capsule or as any other convenient formulation for administration, or rectally, as a suppository, enema or other convenient form.

WO 98/16111

PCT/US97/18845

In a preferred embodiment, an enteric coated pharmaceutical composition containing the proanthocyanidin polymer composition is administered for the treatment or prevention of secretory diarrhea. Preferred enteric coated formulations include, enteric coated beads in a hard-shell gelatin capsule, enteric coated microspheres in a hard-shell gelatin capsule, enteric coated microspheres provided in a suspension or mixed with food, which preparations are particularly convenient for pediatric administration, and enteric coated compressed tablets. In another embodiment, a pharmaceutical composition containing the proanthocyanidin polymer composition and a compound which neutralizes stomach acid or inhibits the secretion of stomach acid is administered for the treatment of secretory diarrhea. In yet another embodiment, a pharmaceutical composition containing the proanthocyanidin polymer composition is administered either concurrent with or subsequent to administration of a pharmaceutical composition which either neutralizes stomach acid or inhibits the secretion of stomach acid for treatment of secretory diarrhea. The proanthocyanidin polymer composition can also be formulated as a suppository for rectal administration.

The pharmaceutical formulations of the invention can also be administered either alone or in combination with other agents for treatment or amelioration of secretory diarrhea symptoms such as rehydration agents, antibiotics, anti-motility agents, and fluid absorbants, such as attapulgite.

The pharmaceutical formulations of the invention can also be incorporated into animal feed for use in treating secretory diarrhea in animals such as bovine animals, swine, ovine animals, poultry, equine animals, canine animals, and feline animals.

The following series of Examples are presented for purposes of illustration and not by way of limitation on the scope of the invention.

WO 98/16111

PCT/US97/18845

6. EXAMPLE: EFFECT OF SIMULATED GASTRIC FLUID,
SIMULATED INTESTINAL FLUID AND
HYDROCHLORIC ACID ON THE
PROANTHOCYANIDIN POLYMER
COMPOSITION FROM *C. lechleri*

5 After per-oral administration of the proanthocyanidin
polymer composition from *C. lechleri*, neither the polymers
nor derivatives of the polymers were detected in either human
or animal plasma samples. However, polymers were detected
and quantitated in plasma of animals following intravenous
10 administration. This led to the hypothesis that the
proanthocyanidin polymer composition, upon oral
administration, is altered in the gastrointestinal tract and
a species which is derived from the proanthocyanidin polymer
composition but is not detectable by the HPLC method used, is
15 then absorbed into the systemic circulation. A second
possibility is that the proanthocyanidin polymer composition
is absorbed intact in the gastrointestinal tract but is
quickly transformed after absorption. There is yet another
possibility that proanthocyanidin polymers of large molecular
20 weight are not absorbed from either the stomach or the
intestine.

Thus, this investigation was performed to gain an
understanding of the effects of HCl, simulated gastric juice
and simulated intestinal fluid on stability of the
25 proanthocyanidin polymer composition from *C. lechleri*. These
conditions were chosen to mimic the chemical conditions of
the digestive tract. Incubation with HCl produced an
approximately 25% reduction in the concentration of the
proanthocyanidin polymer composition within several minutes.
30 A similar reduction of 32% was observed within minutes after
incubation of the proanthocyanidin polymer composition with
simulated gastric fluid (SGF), and a 48% reduction was
observed after 2 hours of incubation. The additional loss
observed after incubation in simulated gastric fluid as
35 compared with the loss observed after incubation in HCl,
could be due to binding of the proanthocyanidin polymer
composition to the pepsin in the simulated gastric fluid.

WO 98/16111

PCT/US97/18845

When, after incubation in simulated gastric fluid, the proanthocyanidin polymer composition-simulated gastric fluid mixture was incubated with simulated intestinal fluid, no further significant reduction in concentration was observed.

5

6.1 MATERIALS AND METHODS

Following per-oral administration, a drug is in contact with gastric fluid for approximately 2 to 3 hours before it passes to the duodenum where the gastric fluid and the drug are mixed rapidly with intestinal fluid. Therefore, to best mimic the in vivo conditions, the proanthocyanidin polymer composition was first incubated in simulated gastric fluid for 2 hours and then diluted with simulated intestinal fluid in the ratio of 1:1 and incubated for an additional 6 hours at 37°C. Additionally, the proanthocyanidin polymer composition was incubated in simulated gastric fluid (SGF), hydrochloric acid (HCl) or water at 37°C. Aliquots were taken from each treatment sample at different time intervals, and the amount of proanthocyanidin polymer composition was quantitated by HPLC.

Preparation of test mixtures and samples:

1. Simulated Gastric Fluid (SGF) was prepared according to USP XX, p. 1105, by dissolving 2.0 g of sodium chloride and 3.2 g of pepsin (from porcine stomach mucosa, Sigma) in 7.0 ml hydrochloric acid and sufficient water (HPLC grade, Fisher) to make 1000 ml. This test solution had a pH of about 1.2.
2. Simulated intestinal Fluid (SIF) was prepared according to USP XX, p. 1105, by dissolving 6.8 g of monobasic potassium phosphate in 250 ml of water and adding 190 ml of 0.2 N sodium hydroxide and 400 ml of water. 10.0 g of pancreatin (from porcine pancreas, Sigma) was then added, mixed and the resulting solution was adjusted to pH 7.5+/-0.1 with 0.2 N NaOH. The solution was diluted with water to 1000 ml.
3. Hydrochloric acid (pH=1.7) was prepared by adding 800 µl of 12 N hydrochloric acid to 100 ml water.

WO 98/16111

PCT/US97/18845

4. Proanthocyanidin polymer stock solution was prepared by dissolving 1.0 g of the proanthocyanidin polymer composition from *C. lechleri* in 10 ml distilled water.

Procedure:

- 5 The proanthocyanidin polymer composition stock solution was diluted 1:20 (to a total volume of 10 ml) in SGF or in purified water. The test solutions were incubated in an oven at 37°C and 1 ml aliquots taken while stirring at time intervals of 0.03, 0.5, and 2.0 hours. After the aliquots
10 were centrifuged for 10 minutes at 14,000 rpm, 700 µl of the supernatant was withdrawn and neutralized with 1N NaOH containing 50 mM dibasic sodium phosphate to a pH of 7.0+/-0.1. At the end of the 2 hour incubation period, SIF was added to the proanthocyanidin polymer composition in SGF in
15 the ratio of 1:1 and the pH adjusted to 7.0+/-0.1. Aliquots were taken and processed as described above at 2, 2.5, 4 and 6 hours after the initial mixture with SGF. The neutralized supernatant was diluted 1:9 in tetrahydrofuran (HPLC grade, Fisher). The samples were assayed by HPLC on a Hewlett
20 Packard 1050 High Performance Liquid Chromatograph using a 5 m PLgel 500A column (Polymer Laboratories) (300 x 7.5 mm) and a 5 m guard column (50 x 7.5 mm), with a mobile phase of 95% tetrahydrofuran and 5% water, an injection volume of 50 µl, a flow rate of 1 ml/min and a run time of 11 minutes. The
25 proanthocyanidin polymers were detected by assaying for UV absorption at a wavelength of 280 nm.

6.2 RESULTS AND DISCUSSION

- The HPLC method used for quantitating the
30 proanthocyanidin polymer composition did not include derivitization or ion-exchange and measures the unbound or "free" proanthocyanidin polymers and not the proanthocyanidin polymers bound to protein. Additionally, the HPLC chromatography is based on size exclusion chromatography and
35 thus detects changes in the molecular size (polymerization or degradation) of the proanthocyanidin polymers but not

WO 98/16111

PCT/US97/18845

chemical alterations which do not affect the size or molar extinction coefficient at 280 nm.

Effect of HCl on the proanthocyanidin polymer composition:

To test the effect of HCl (a major component of gastric fluid) on the proanthocyanidin polymer composition from *C. lechleri* in vitro, the proanthocyanidin polymer composition was incubated for 2 hours in HCl at pH 1.2. Samples were taken after 0.03, 0.5 and 2.0 hours of incubation and analyzed using HPLC. The peak area for the HPLC profile of the proanthocyanidin polymer composition after incubation in HCl was compared to the peak area for the profile of the proanthocyanidin polymer composition after incubation in water (Table 1).

TABLE 1. EFFECT OF HYDROCHLORIC ACID (PH = 1.7) ON THE PROANTHOCYANIDIN POLYMER COMPOSITION.

Time, h	Sample #1 % Peak Area	Sample #2 % Peak Area	Average (n=2)
0.03	94	67	81
0.5	73	71	72
2.0	77	70	74

* % Peak area was calculated by dividing peak area of the profile of the proanthocyanidin polymer composition in the test-medium by peak area of the profile of the proanthocyanidin polymer composition in water (control) and multiplying by 100.

Results indicate that after 0.03 hours in HCl, the peak area of the proanthocyanidin polymer composition profile, i.e. the concentration of the proanthocyanidin polymer composition, was reduced by 19%. After 0.5 hours and 2.0 hours incubation with HCl, the peak area of the proanthocyanidin polymer profile was reduced by 28% and 26%, respectively. These results indicate that most of the decrease of the proanthocyanidin polymer composition due to HCl exposure occurred within the first 2-3 minutes of incubation.

Figure 1 shows sample chromatograms of the proanthocyanidin polymer composition after incubation in water and in HCl for 0.03 hours, and in HCl for 2.0 hours.

WO 98/16111

PCT/US97/18845

In addition to the obvious reduction in the area of the peak of the proanthocyanidin polymer profile after incubation for 2 hours in HCl, a noticeable shift in the retention time of the shoulder was observed. A possible interpretation of the observed shift in retention time of the shoulder from 5.8 to 6.2 min after incubation of the composition in HCl is that HCl breaks down the proanthocyanidin polymers into subunits of slightly lower molecular weight with retention times longer than the retention time of the parent compound.

10 Effects of SGF on the Proanthocyanidin Polymer Composition:

When the proanthocyanidin polymer composition from *C. lechleri* was added to SGF, the mixture formed an opaque red precipitate. To determine if the precipitate was due to pepsin or sodium chloride, the proanthocyanidin polymer composition was added at a final concentration of 5 mg/ml to either SGF without sodium chloride or to SGF without pepsin. After the samples were centrifuged at 14,000 rpm for 10 min, only the mixture containing pepsin was opaque red with precipitation, indicating that the precipitation is due to the interaction of the proanthocyanidin polymer composition with pepsin.

After a 2 minute (0.03 hour) incubation of the proanthocyanidin polymer composition solution in SGF, HPLC analysis showed an approximately 32% reduction in the peak area of the proanthocyanidin polymer profile. The samples taken 0.5 and 2.0 hours after incubation at 37°C showed no further significant change the peak area of the proanthocyanidin polymer profile. Chromatograms of the proanthocyanidin polymer samples incubated for 2 minutes and 2 hours in SGF are presented in Figures 2 and 3, respectively, and the peak area data from this experiment are shown in Table 2.

35

WO 98/16111

PCT/US97/18845

TABLE 2. EFFECT OF SGF ON THE PROANTHOCYANIDIN POLYMER COMPOSITION IN VITRO.

Time, h	Sample #1 % Peak Area	Sample #2 % Peak Area	Average (n=2)
0.03	59	76	68
0.5	70	67	69
2.0	54	49	52
6.0	45	55	50

% Peak Area was calculated by dividing peak area of the profile of the proanthocyanidin polymer composition in the test-medium by peak area of the profile of the proanthocyanidin polymer composition in water (control) and multiplying by 100.

Most of the reduction in the concentration of the proanthocyanidin polymers occurred within 2 minutes of exposure to SGF. Furthermore, the decrease in the proanthocyanidin polymer composition detected by the HPLC assay might be due to a combination of the effects of degradation by the acid in the SGF and binding to the pepsin in the SGF.

The rapid decrease in peak area under the curve following the addition of the proanthocyanidin polymer composition to SGF solution is demonstrated in Figures 4 and 5 which show sample chromatograms of the proanthocyanidin polymer composition after 2 minutes and 2 hours of incubation in SGF respectively.

Effect of SIF on the Proanthocyanidin Polymer Composition:

To better understand the fate of the proanthocyanidin polymer composition from *C. lechleri* in the small intestines, the effect of intestinal fluid on the proanthocyanidin polymer composition was investigated in vitro. To best mimic the in vivo conditions, the proanthocyanidin polymer composition was first incubated in simulated gastric fluid for 2 hours and then diluted with simulated intestinal fluid in the ratio of 1:1 and incubated for an additional 6 hours at 37°C. Samples withdrawn at various time intervals following addition of SIF to the proanthocyanidin polymer

WO 98/16111

PCT/US97/18845

composition-SGF solution were analyzed by HPLC. Representative chromatograms are presented in Figures 4 and 5. The results are shown in Table 3 and Figure 6 and indicate that SIF did not significantly reduce the amount of 5 proanthocyanidin polymer composition.

TABLE 3. INTERACTION OF SIF WITH SGF-PROANTHOCYANIDIN POLYMER COMPOSITION MIXTURE FOLLOWING 2 HOUR INCUBATION IN SGF FOLLOWED BY A 4 HOUR INCUBATION AFTER 1:1 DILUTION IN SIF.

10	Time, h	Sample #1 % Peak Area	Sample #2 % Peak Area	Average (n=2)
	2.0	44	52	48
	2.5	50	42	46
	4.0	59	45	52
15	6.0	45	55	50

% Peak Area was calculated by dividing peak area of the profile of the proanthocyanidin polymer composition in the test-medium by peak area of the profile of the proanthocyanidin polymer composition in water (control) and multiplying by 100.

20

6.3 CONCLUSION

The incubation conditions tested in this study mimic the conditions encountered by the proanthocyanidin polymer composition from *C. lechleri* following peroral administration. Some loss of the proanthocyanidin polymer composition (25-32%) was observed within minutes of incubation of the composition with dilute HCl and SGF. The greater loss observed after incubation in SGF as compared to the loss after incubation in HCl could be caused by the binding of the proanthocyanidin polymer composition to the pepsin in the SGF. When the solution of the proanthocyanidin polymer composition in simulated gastric fluid was incubated with simulated intestinal fluid, no further significant reduction in the proanthocyanidin polymer composition was observed.

35

Because the method used to analyze the proanthocyanidin polymer composition was based on size exclusion

WO 98/16111

PCT/US97/18845

chromatography, caution should be used in the interpretation of the results presented here because the method is unable to differentiate between native proanthocyanidin polymer composition and a proanthocyanidin polymer composition that
5 has been chemically altered in a way that does not significantly change its size.

10 7. **EXAMPLE: ASSESSMENT OF THE EFFECT OF ENTERIC COATED PROANTHOCYANIDIN POLYMER COMPOSITION ON FLUID ACCUMULATION IN CHOLERA TOXIN-TREATED MICE**

The purpose of this study was to determine the effect of enteric-coated proanthocyanidin polymer composition prepared from *Croton lechleri* on fluid accumulation in the intestinal tract of mice treated with cholera toxin (CT). The
15 pathophysiological mechanism by which cholera toxin produces fluid accumulation in mice is identical to the mechanism by which cholera toxin and other bacterial toxins produce fluid accumulation in humans. Reduction of the fluid in this model by a test compound indicates that the compound is useful as
20 an antidiarrheal agent. At initial time (t_0), mice received cholera toxin (15 μ g per average body weight of approximately 20 g) by oral gavage and were anorectally sealed with a cyano-acrylamide ester. Three hours later (t_3 h), a single dose of enteric coated proanthocyanidin polymer composition
25 (131 mg/kg) suspended in 0.75% guar gum (vehicle) was administered by oral gavage. Water and a control solution consisting of an equivalent concentration of "EUDRAGIT™" and sugar in vehicle were also administered to two control groups. After a 7 hour (t_7 h) exposure to cholera toxin, mice
30 were sacrificed and the entire murine intestinal tract from the pylorus to the rectum, including cecum, was isolated. The entire murine intestinal tract was isolated because, although fluid accumulation occurs in the small intestine, some fluid does leak into the large intestine. Fluid
35 accumulation (FA) was measured as the ratio of the mass of accumulated fluid in the intestinal tract and rectum, including cecum, versus the mass of the intestinal tract

WO 98/16111

PCT/US97/18845

minus the mass of the fluid. Under the experimental conditions, orally administered enteric coated proanthocyanidin polymer composition was shown to significantly reduce fluid accumulation in the intestinal tract of sealed adult mice treated with cholera toxin. Oral administration of enteric coated proanthocyanidin polymer composition (131 mg/kg) reduced the fluid accumulation ratio by an average of 45% and 38% compared to the mean fluid accumulation ratio in water controls and "EUDRAGIT"/sugar/vehicle controls, respectively.

7.1 PREPARATION OF CHOLERA TOXIN AND THE PROANTHOCYANIDIN POLYMER COMPOSITIONS

The following materials were obtained from commercial suppliers: cholera toxin (List Biological Lab, lot # CVX-48-3D); cyano-acrylamide ester (Borden Inc., Columbus, OH); animal feeding needles (Popper and Sons, Hyde Park, NY); sodium bicarbonate (ACROS lot # 83559/1); guar gum (Sigma, lot # 94H0195); "EUDRAGIT" L30D" (PMRS, lot # R10538); 40-60 mesh sugar spheres (PMRS, lot # R10542).

To prepare the cholera toxin stock solution, one milliliter of HPLC grade water (Mill Q) was added to a vial containing 1 mg of cholera toxin and two different vials were pooled and stored at 4°C. Cholera toxin solutions for administration to animals were freshly prepared by diluting 240 μ l cholera toxin stock solution with 560 μ l 7% w/vol NaHCO₃. Final concentration of NaHCO₃ was 4.9%. Each mouse received 15 μ g of cholera toxin in 50 μ l volume by oral gavage at initial time (t_0).

The formulation for the enteric coated proanthocyanidin polymer composition from *C. lechleri* contained 17.3% (w/w) of nonpareil seeds (sugar spheres, 46/60 mesh) (Paulaur, lot # 60084060), 64.6% proanthocyanidin polymer composition, 1.5% hydroxypropylmethylcellulose (HPMC, Dow Chemical Co., lot # MM9410162E), 0.5% Opadry Clear (Colorcon, lot # S835563), 14.5% "EUDRAGIT" L 30D" (Rohm Tech., lot # 1250514132), 1.45% triethyl citrate (Morflex,

WO 98/16111

PCT/US97/18845

lot # N5X291), glyceryl monostearate (Rohmm Tech, lot # 502-229), and purified water (USP).

The solution for layering the proanthocyanidin polymer composition onto the sugar spheres was prepared by adding 5 HPMC and the proanthocyanidin polymer composition to purified water (USP) and mixing until dissolved. The nonpareil seeds were loaded into the product bowl of the fluid bed processor (Niro-Precision Coater). The proanthocyanidin polymer composition/HPMC solution was then sprayed onto fluidized 10 nonpareil seeds, while maintaining the target bed temperature at 30-35°C. The layering process was continued until all the solution had been applied. Once the proanthocyanidin polymer composition layering had been completed, a seal coat of Opadry Clear (prepared by mixing the Opadry Clear with 15 Purified Water, USP) was applied, maintaining the target bed temperature at 30-35°C. When the seal coat had been applied, the pellets were discharged and screened through 1000 μ and 425 μ screens and the layered spheres larger than 425 μ and smaller than 1000 μ were charged back into fluid bed 20 processor. Meanwhile, the enteric coating solution was prepared by adding triethyl citrate and glyceryl monostearate to water that had been heated to 65°C with continued mixing. This solution was added to the "EUDRAGIT" L 30D-55" while mixing. The resulting enteric coating solution was then 25 sprayed onto the layered spheres in the fluidized bed processor, at a bed temperature of 30-35°C until all enteric coating solution was layered on the beads.

To facilitate oral gavage and prevent instantaneous settling of the beads, a thickening agent, guar gum was used. 30 One hundred ml of 0.7% guar gum was prepared and adjusted to pH 2 with 2 ml of 0.5 M HCl. The enteric coated proanthocyanidin polymer composition beads were suspended in 0.7% guar gum solution. A control solution consisting of equivalent final concentrations of "EUDRAGIT" and sugar was 35 also prepared in 0.7% guar gum solution.

WO 98/16111

PCT/US97/18845

7.2 METHODS AND RESULTS

The experiments were performed according to Richardson and Kuhn, 1986, *Infect. and Immun.* 54: 522-528. 50- to 52-day-old male mice with body masses that ranged from 15.7 to 18.7 g were used. Test animals were wild type C57Bl/6 mice and were obtained from Charles River Lab. All animals were maintained in metabolism cages with water *ad libidum* for the duration of the experiment. Mice were deprived of food for 24 hours prior to start of the experiment and during the course of experimentation. Initially (t_0 h), the mice received 15 μ g cholera toxin by oral gavage and were anorectally sealed with a cyano-acrylamide ester (Superglue). Three hours later (t_3 h), the mice received by oral gavage either a suspension of the enteric coated proanthocyanidin polymer composition in guar gum solution or a control solution. After a 7 hour (t_7 h) exposure to cholera toxin, mice were sacrificed and the entire murine intestinal tract from the pylorus to the rectum, including cecum, was isolated. Care was taken to avoid tissue rupture and loss of fluid, and the attached mesentery and connective tissue were then removed. The mass of tissue and the fluid within was determined using an analytical balance. The tissue was then opened longitudinally, the fluid removed, and the tissue was patted dry. Fluid accumulation was measured as the ratio of the mass of accumulated fluid in the intestine (small and large including cecum) versus the mass of the intestine minus the mass of the fluid.

Statistical comparisons of the fluid accumulation ratio for different treatments were made by analysis of variance using Microsoft Excel (version 5.0). A p-value of $p < 0.05$ was used to determine significance. Duncan's multiple range test was carried out to determine whether statistically significant reductions in cholera toxin-induced fluid accumulation ratios occurred in the mice that received the enteric coated proanthocyanidin polymer composition compared to animals that received only H₂O or "EUDRAGIT™" plus sugar in 0.75% guar gum solution.

WO 98/16111

PCT/US97/18845

In the experiment described below, a total of 24 mice (8 mice per each treatment) were treated as follows:

Group A: Mice received cholera toxin at t_0 followed by a single dose of water at t_3 and were sacrificed at t_7 after 5 administration of cholera toxin.

Group B: Mice received cholera toxin at t_0 . At t_3 , the mice received a single dose of enteric coated proanthocyanidin polymer composition (131 mg/kg body weight). The vehicle consisted of acidified 0.75% guar gum solution. 10 All animals were sacrificed at t_7 .

Group C: Mice received cholera toxin at t_0 . At t_3 , the mice received a single dose of an equivalent concentration of "EUDRAGIT™" and sugar (1.33 mg of "EUDRAGIT™" plus 1.046 mg of sugar/kg body weight). The vehicle consisted of acidified 15 0.75% guar gum solution. All animals were sacrificed at t_7 .

Based on the preliminary studies which indicated the need for longer incubation time to assure complete transfer of the coated beads into the intestine, all animals were sacrificed at t_7 after cholera toxin dosing. To achieve more 20 reliable results, the number of animals was increased to 8 mice for each group. Table 4 and Figure 7 show the effect of enteric coated proanthocyanidin polymer composition on cholera toxin-induced fluid secretion in the sealed adult mouse model. As could be seen, a single dose of 131 mg 25 proanthocyanidin polymer composition/kg significantly ($P < 0.05$) reduced cholera toxin-induced fluid accumulation after a seven hour incubation with cholera toxin. Compared to the results after control treatments (groups A and C), enteric coated proanthocyanidin polymer composition beads 30 (group B) significantly reduced the ratio of fluid accumulation by an average of 45% and 38% respectively.

In this experiment, none of the mice died as a result of treatment by oral gavage.

35

WO 98/16111

PCT/US97/18845

TABLE 4. THE EFFECT OF ENTERIC COATED PROANTHOCYANIDIN POLYMER COMPOSITION BEADS ON INTESTINAL FLUID ACCUMULATION IN CHOLERA TOXIN-TREATED MICE

	Group	No. of Mice	Treatment	Fluid Accumulation* (mg fluid/mg intestine)
5	A	8	H ₂ O	1.28 ± 0.09 a
	B	8	131 mg proanthocyanidin polymer composition in guar gum solution/kg	0.71 ± 0.17 b
10	C	8	"EUDRAGIT™" & sugar/guar gum solution	1.15 ± 0.16 a

* Values with different letters differ significantly (p<0.05) by Duncan's Multiple Range Test.

Under the experimental conditions, enteric coated proanthocyanidin polymer composition significantly reduced fluid accumulation in the intestine of sealed adult mice treated with cholera toxin. Based on these results, oral administration of the enteric coated proanthocyanidin polymer composition (131 mg/kg) reduced the fluid accumulation ratio by an average of 38%, compared to the mean fluid accumulation ratio in "EUDRAGIT™" plus sugar controls.

Results of a further experiment using 18-20 mice per group are presented in Figure 8 and Table 5, and these results confirm the results from the initial experiment. Mice in group B, which received 131 mg of the proanthocyanidin polymer composition/kg three hours (t₃) after exposure to cholera toxin, exhibited significant reduction in fluid accumulation as compared to mice which received "EUDRAGIT™" and sugar in water at t₃.

35

WO 98/16111

PCT/US97/18845

TABLE 5: THE EFFECT OF ENTERIC COATED PROANTHOCYANIDIN POLYMER COMPOSITION BEADS ON INTESTINAL FLUID ACCUMULATION IN CHOLERA TOXIN-TREATED MICE

	Grp.	No. of Mice	t ₀ hr	t ₃ hr	Fluid Accumulation (mg fluid/mg intestine)
5	A	20	CT/NaHCO ₃	"EUDRAGIT" & Sugar/H ₂ O	1.34 ± 0.09a*
	B	18	CT/NaHCO ₃	131 mg/kg proantho-cyanidin polymer composition	0.75 ± 0.10 b*
10					

* Values with different letters differ significantly (P<0.001) by T-test.

8. EXAMPLE: PREPARATION OF PHARMACEUTICAL FORMULATIONS

Described below are illustrative methods for the manufacture and packaging for different preferred pharmaceutical formulations of the proanthocyanidin polymer composition from *C. lechleri* according to the present invention.

8.1. ENCAPSULATED ENTERIC COATED BEADS

Detailed descriptions of the batch formula and methods used to prepare the encapsulated enteric coated proanthocyanidin polymer composition bead formulation are provided below. Each hard-shell gelatin capsule contained 250 mg proanthocyanidin polymer composition enteric coated beads. Capsules were packaged in HDPE bottles containing sixteen (16) 250 mg caps each. The formulation for enteric coated proanthocyanidin polymer composition beads contained 17.3% (w/w) of nonpareil seeds (sugar spheres 40/60 mesh, Paulaur, lot #60084060), 64.5% proanthocyanidin polymer composition from *C. lechleri*, 1.5% hydroxypropylmethylcellulose (Methocel E5 Premium, Dow Chemical Co., lot #MM9410162E), 0.5% Opadry Clear (Colorcon, lot #S83563), 14.5% "EUDRAGIT" L30D" (Rohm Tech., lot #1250514132), 1.45% triethyl citrate (Morflex, lot #N5X291),

WO 98/16111

PCT/US97/18845

glyceryl monostearate (Imwitor-900, Rohm Tech, lot #502-229), and purified water (USP).

The layering coating solution containing the proanthocyanidin polymer composition was prepared by adding 5 hydroxypropylmethylcellulose and the proanthocyanidin polymer composition to purified water (USP) and mixing until dissolved. The nonpareil seeds were loaded into the product bowl of the fluid bed processor (Nior-Precision Coater). The polymer solution was then layered on the nonpareil seeds by 10 spraying the solution onto the fluidized nonpareil seeds at a target bed temperature of 30-35°C. Once the proanthocyanidin polymer layering had been completed, a seal coat using Opadry Clear (preparing by mixing the Opadry Clear with Purified Water, USP) was applied with a target bed temperature of 30-15 35°C. After the seal coat was applied, the pellets were discharged and screened through 1000 μ and 425 μ screens, and the layered spheres larger than 425 μ and smaller than 1000 μ were charged back into the fluid bed processor. Meanwhile, the enteric coating solution was prepared by mixing triethyl 20 citrate and glyceryl monostearate to water that had been heated to 65°C and then mixing this solution with the "EUDRAGIT™ L30D-55". The resulting enteric coating solution was then sprayed onto the layered spheres in the fluidized bed processor, at a bed temperature of 30-35°C, until all the 25 enteric coating solution was layered on the beads. Based on the results of the HPLC assay indicating that the proanthocyanidin polymer composition was present at a concentration of 52.9%, the enteric coated beads were hand filled into a Size #0 hard shell gelatin capsule to provide a 30 250 mg dosage and then packaged into a suitable HDPE bottles with a heat induction lined cap.

35

WO 98/16111

PCT/US97/18845

TABLE 6: BATCH FORMULA

Product: Proanthocyanidin Polymer Enteric Coated Beads		
Batch Size: 578.0 gm		
5	<u>Raw Material</u>	<u>Amount Used Per Batch</u>
	Sugar Nonpareil Spheres, NF (40/60)	100.0 gm
	Proanthocyanidin Polymer Composition	372.8 gm
10	Hydroxypropylmethylcellulose E5, USP (K29/32)	8.7 gm
	Opadry Clear (YS-1-19025A)	2.9 gm
	"EUDRAGIT" L 30D-55" (30% solids)	279.4 gm
15	Triethyl Citrate, NF	8.4 gm
	Glycerol Monostearate	1.4 gm
	Water, USP (Removed during processing)	1284.8 gm

8.2. ENTERIC COATED GRANULES AND POWDER PARTICLES

20 Described below is a method for formulating the proanthocyanidin polymer composition as enteric coated granules or powder (microspheres with a diameter of 300-500 μ) in either hard shell gelatin capsules or suspended in an oral

25 solution. The proanthocyanidin polymer composition powder particles are prepared by high-shear powder mixing of the proanthocyanidin polymer composition and hydroxypropylmethylcellulose in a high speed mixer/granulator. The proanthocyanidin polymer composition

30 granules are prepared by spraying polyvinylpyrrolidone on the powder in the high speed mixer/granulator so that the powder particles agglomerate to form larger granules. Using fluidized bed equipment, the granules or powder are then covered with a seal coat of Opadry Clear (mixed with water) and then coated with the enteric coating "EUDRAGIT" L 30D"

35 applied as an aqueous dispersion containing 30% w/w dry methacrylate polymer substance, which is supplied with 0.7%

WO 98/16111

PCT/US97/18845

sodium lauryl sulfate NF (SLS) and 2.3% polysorbate 80 NF (Tween 20) as emulsifiers, to which the plasticizers, triethyl citrate and glyceryl monostearate, are added to improve the elasticity of the coating. The final composition of the enteric coated powder is 81.8% w/w proanthocyanidin polymer composition, 1.5% w/w hydroxypropylmethylcellulose, 0.5% w/w Opadry clear, 14.5% w/w "EUDRAGIT" L 30D", 1.45% w/w triethyl citrate, and 0.25% w/w glyceryl monostearate. The final composition of the enteric coated granules is 81.8% w/w proanthocyanidin polymer composition, 10% polyvinylpyrrolidone, 1.5% w/w hydroxypropylmethylcellulose, 0.5% w/w Opadry clear, 14.5% w/w "EUDRAGIT" L 30D", 1.45% w/w triethyl citrate, and 0.25% w/w glyceryl monostearate.

The enteric coated proanthocyanidin polymer composition granules or particles may be filled into a hard shell gelatin capsule in an amount which provides a suitable dosage.

The enteric coated proanthocyanidin polymer composition granules or powder particles can also be suspended in a solution for oral administration, particularly for pediatric administration. The suspension solution is prepared by wetting 2 grams hydroxypropylmethylcellulose in 97.8 ml distilled water and 0.2 grams Tween 80; mixing this preparation to homogeneity by sonicating, heating the solution to 40°C and stirring for three hours; and then adding the enteric coated proanthocyanidin polymer composition powder particles or granules to the homogeneous solution.

8.3. ENTERIC COATED COMPRESSED TABLETS

A method for formulating the proanthocyanidin polymer composition as enteric coated tablets is described below. For each 350 mg tablet, 250 mg proanthocyanidin polymer composition is granulated with 7 mg crosslinked sodium carboxymethylcellulose ("AC-DI-SOL") and a sufficient mass of microcrystalline cellulose ("AVICEL" PH 200/300") to bring the total mass to 350 mg. These ingredients are mixed for 20 to 30 minutes in a V blender. After the 20 to 30 minutes of

WO 98/16111

PCT/US97/18845

mixing, 1.75 mg magnesium stearate is added and the mixture is blended for an additional 4 to 5 minutes. The resulting granules are compressed on a rotary tablet press using 5/16th inch standard concave punches. The tablets are coated with an enteric coating mixture prepared from 250 grams "EUDRAGIT" L 30 D-55", 7.5 grams triethyl citrate, 37.5 grams talc and 205 grams water. The tablets are then placed in a perforated pan coater (e.g. the "ACCELA-COTA" system) and rotated at 15 rpm at 40°C. The enteric coating formulation is sprayed using the following conditions: inlet air temperature of 44°C-48°C, exhaust air temperature of 29°C-32°C, product temperature of 26°C-30°C, a 1 mm spray nozzle, a pan speed of 30 to 32 rpm, an airflow of 30-32 CFM, and a spray pressure of 20 PSI. The tablets are finally cured for 30 minutes as the pan is rotating at 15 rpm with an inlet air temperature of 60°C and then, after shutting off the heat, the tablets are rotated at 15 rpm until the tablets have cooled to room temperature.

20

8.4. SUPPOSITORIES

Formulation of the proanthocyanidin polymer composition as a suppository for rectal administration is described below. One suppository formulation for the proanthocyanidin polymer composition can be prepared by heating 91 grams glycerin to 120°C, dissolving 9 grams sodium stearate in the heated glycerin, then adding 5 grams purified water. 5% to 50% proanthocyanidin polymer composition is added to the base and the mixture is then poured into a suitable mold. Alternatively, the suppository may be prepared by heating 20 grams gelatin and 70 grams glycerin to 70°C and stirring for 2 hours, then adding 10 grams proanthocyanidin polymer composition which has been dissolved in purified water by sonicating for 5 minutes, and stirring at 40°C until a homogeneous mixture is achieved. The preparation may then be poured into a mold suitable for preparing suppositories.

WO 98/16111

PCT/US97/18845

**9. EXAMPLE: EFFECT OF THE PROANTHOCYANIDIN POLYMER
COMPOSITION FORMULATIONS IN PATIENTS
SUFFERING FROM TRAVELER'S OR
NON-SPECIFIC DIARRHEA**

Summarized below are interim results obtained from the
5 initial 20 patients of an open-label clinical trial of safety
and effectiveness of the proanthocyanidin polymer composition
from *C. lechleri* for the symptomatic treatment of acute non-
specific diarrhea and traveler's diarrhea.

10 9.1 HUMAN SAFETY AND EFFICACY STUDY

A total of 20 patients with traveler's diarrhea were
entered into the study. The patient population consisted of
young (average age = 24 years) male and female patients who
were students from the United States in Mexico. The students
15 were recruited by the investigator as they entered the
country and were told to report to the clinic after
developing diarrhea and before starting any other
medications.

Subjects were evaluated for the following parameters:

- 20 a) Usual stool frequency (number of stools per day or
week).
- b) Date and time of diarrhea onset.
- c) Number of stools in the past 24 hours, categorized
according to consistency as follows:
- 25 - Formed: retains its original shape in water
- Soft: assumes shape of the container
- Watery: can be poured
(Stools of mixed form (e.g., soft/watery) were
classified in the least formed category (e.g.,
30 watery)).
- d) Symptoms experienced during the past 24 hours,
including:
- 35 - Cramping
- Anal irritation
- Tenesmus
- Urgency (inability to delay timing by as long as
15 minutes)

WO 98/16111

PCT/US97/18845

- Fecal incontinence (decreased control of bowel movements)
- Inconvenience (interference with normal activities)
- 5 - Nausea
- Vomiting
- Increased intestinal gas

After completion of the screening evaluations, samples for the baseline laboratory tests were obtained and the first
10 dose of study medication was administered. The subjects were administered an initial loading dose of 1250 mg of the enteric coated proanthocyanidin polymer composition with three more doses of 250 mg every six hours for the first 24 hours of treatment, and then 500 mg four times per day for a
15 total of 2 grams per day on the second day of dosage. The proanthocyanidin polymer composition was only administered for two days.

During the baseline clinic visit, the study participants were trained to accurately complete the diary and study
20 forms, and the following evaluation parameters were considered:

1. Safety

Patients were asked about any adverse events experienced during the study. These events were categorized as to the
25 severity, duration, relationship to study drug and any action taken. Blood and urine obtained at entry and at study completion were used to assess any changes.

2. Efficacy

Efficacy was assessed from the patient diary and clinic
30 visits. The key efficacy parameters measured were the stool frequency, consistency and the time-to-last-unformed-stool.

9.2 RESULTS

During the study, no significant adverse effects were
35 observed in any of the subjects that could be attributed to the proanthocyanidin polymer composition. The primary efficacy parameters for this trial included self-reported

WO 98/16111

PCT/US97/18845

stool frequency and time to last unformed stool. These data are summarized in Table 7.

TABLE 7: REPORTED STOOL FREQUENCY (20 PATIENTS TREATED)

5	Time	Stools per Day (Mean).
	24 Hours prior to entry	5.6
	Day 1	4.0
	Day 2	2.9
	Day 3	2.1
10	Usual	1.6

On average, the abnormal stool frequency trended toward normal over the three days of the study. The average number of stools per day returned to near-normal frequency by day 3.
 15 4 patients returned to their normal stool frequency by the third study day. In addition, the time-to-last-unformed-stool was 30.3 hours on average.

Baseline and follow-up reports of gastrointestinal symptoms were obtained. Patients were asked to score the
 20 severity (mild, moderate or severe) of nine symptoms, including nausea, vomiting, cramping, gas, urgency, tenesmus, anal irritation, incontinence and inconvenience.

A total of 9 patients completely resolved their symptoms by the end of the 3 day study. Table 8 presents the number
 25 of patients who resolved all symptoms by the time indicated.

TABLE 8: RESOLUTION OF ALL SYMPTOMS BY TIME (20 PATIENTS TREATED)

	Time	Number of Patients Resolved
30	24 hours	1
	48 hours	2
	60 hours	4
	72 hours	2

35 A total score for the symptoms was obtained by assigning a score of 0 to the absence of symptoms, 1 to mild, 2 to moderate and 3 to severe symptoms. The total scores for all

WO 98/16111

PCT/US97/18845

patients at each time period were averaged and are presented in Table 9.

TABLE 9: SYMPTOM SCORE BY TIME (20 PATIENTS TREATED)

5	Time	Average Score
	Entry	8.9
	12 hours	6.1
	24 hours	4.5
	36 hours	3.8
10	48 hours	3.0
	60 hours	1.8
	72 hours	1.1

Based on our review of the data, we have reached the
15 following conclusions:

1. While the drug was generally well tolerated, 3
patients experienced severe, self-limited nausea which was
possibly related to study drug. However, none of the
patients were withdrawn from the study due to an adverse
20 event.

2. No significant changes in serum chemistry or
hematology occurred during the treatment period. Six
patients did experience mild changes in their urinalysis. We
do not believe that these changes in urinalysis represent
25 significant adverse effects. It was unclear if these changes
were a result of the study drug or evolution of their
underlying illness.

3. Stool frequency tended to return to normal
frequency over the 3 day study period.

30 4. The average time-to-last-unformed-stool was 30.3
hours compared to a reported 69 hours in historical controls.

In summary, we further conclude that an enteric
formulation of the proanthocyanidin polymer composition from
C. lechleri is useful for the amelioration of stool frequency
35 and gastrointestinal symptoms in patients afflicted by
traveler's diarrhea. Overall the drug appears to be safe,
with nausea being the most common event.

WO 98/16111

PCT/US97/18845

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed since these embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments
5 are intended to be within the scope of this invention.

Indeed, various modifications of the invention in addition to those shown and described therein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope
10 of the appended claims.

All publications cited herein are incorporated by reference in their entirety.

15

20

25

30

35

WO 98/16111

PCT/US97/18845

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin polymer composition isolated from a Croton spp. or from a Calophyllum spp. or a pharmaceutically acceptable derivative thereof formulated to protect the proanthocyanidin polymer composition from the action of stomach acid; and a pharmaceutically acceptable carrier.
- 10 2. The pharmaceutical composition of claim 1, in which the Croton spp. is *Croton lechleri*.
3. The pharmaceutical composition of claim 1, in which the composition comprises an enteric coating.
- 15 4. The pharmaceutical composition of claim 3, in which the composition is formulated as a capsule, which capsule is or is not enteric coated.
- 20 5. The pharmaceutical composition of claim 3, in which the enteric coating is comprised of a methacrylic acid-methacrylic acid ester copolymer with acid ionizable groups.
6. The pharmaceutical composition of claim 5, in which
25 the enteric coating further comprises one or more plasticizer compounds.
7. The pharmaceutical composition of claim 6, in which the plasticizer compounds are polyethylene glycol ester and
30 citric acid ester.
8. The pharmaceutical composition of claim 7, in which the composition is formulated as a compressed tablet.
- 35 9. The pharmaceutical composition of claim 7, in which the composition is formulated as a capsule containing beads, which beads comprise a sugar sphere, a layer of the

WO 98/16111

PCT/US97/18845

proanthocyanidin polymer composition and a layer of the enteric coating.

10. The pharmaceutical composition of claim 7, in which
5 the composition is formulated as microspheres of 300 microns to 500 microns, which microspheres comprise granules of the proanthocyanidin polymer composition and a layer of the enteric coating.

10 11. The pharmaceutical composition of claim 10, in which the microspheres are filled into a capsule.

12. The pharmaceutical composition of claim 10, in which the microspheres are further formulated in a
15 suspension.

13. The pharmaceutical composition of claim 1, in which the proanthocyanidin polymer composition is formulated with a substance which inhibits the secretion of stomach acid.

20

14. The pharmaceutical composition of claim 1, in which the proanthocyanidin polymer composition is formulated with a substance than neutralizes stomach acid.

25 15. A pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin polymer composition isolated from a Croton spp. or from a Calophyllum spp. or a pharmaceutically acceptable derivative thereof, which is formulated as a suppository in a
30 pharmaceutically acceptable carrier.

16. A method of treatment for secretory diarrhea in animals, including humans, comprising: administering, to a non-human animal or human suffering from diarrhea, a
35 pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin polymer composition isolated from a Croton spp. or a Calophyllum spp. or a

WO 98/16111

PCT/US97/18845

pharmaceutically acceptable derivative thereof formulated to protect the proanthocyanidin polymer composition from the action of stomach acid, and a pharmaceutically acceptable carrier.

5

17. The method of claim 16, in which the *Croton* spp. is *Croton lechleri*.

18. The method of claim 16, in which the composition
10 comprises an enteric coating.

19. The method of claim 18, in which the composition is formulated as a capsule, which capsule is or is not enteric coated.

15

20. The method of claim 18, in which the enteric coating is comprised of a methacrylic acid-methacrylic acid ester copolymer with acid ionizable groups.

20 21. The method of claim 20, in which the enteric coating further comprises one or more plasticizer compounds.

22. The method of claim 21, in which the plasticizer compounds are polyethylene glycol ester and citric acid
25 ester.

23. The method of claim 22, in which the composition is formulated as a compressed tablet.

30 24. The method of claim 22, in which the composition is formulated as a capsule containing beads, which beads comprise a sugar sphere, a layer of the proanthocyanidin polymer composition and a layer of the enteric coating.

35 25. The method of claim 22, in which the composition is formulated as a capsule containing microspheres of 300 microns to 500 microns, which microspheres comprise granules

WO 98/16111

PCT/US97/18845

of the proanthocyanidin polymer composition and a layer of the enteric coating.

26. The method of claim 16, in which the
5 proanthocyanidin polymer composition is formulated with a substance which inhibits the secretion of stomach acid.

27. The method of claim 16, in which the
proanthocyanidin polymer composition is formulated with a
10 substance that neutralizes stomach acid.

28. The method of claim 16 in which the diarrhea is caused by a bacterium.

15 29. The method of claim 28, in which the bacterium is selected from the group of *Escherichia coli*, *Vibrio* spp., *Campylobacter* spp., *Salmonella* spp., *Aeromonas* spp., *Plesiomonas* spp., *Shigella* spp., *Klebsiella* spp., *Citrobacter* spp., *Yersinia* spp., *Clostridium* spp., *Bacteriodes* spp.,
20 *Staphylococcus* spp., and *Bacillus* spp.

30. The method of claim 29, in which the bacterium is either enterotoxigenic *Escherichia coli* or *Campylobacter jejuni*.
25

31. The method of claim 16, in which the secretory diarrhea is caused by a non-infectious etiology.

32. The method of claim 31, in which the non-infectious
30 etiology is selected from the group consisting of non-specific diarrhea, ulcerative colitis, inflammatory bowel syndrome, and cancers and neoplasias of the gastrointestinal tract.

33. The method of claim 16, in which the human
35 suffering from diarrhea is an infant or a child.

WO 98/16111

PCT/US97/18845

34. The method of claim 16, in which a human is treated for HIV-Associated Chronic Diarrhea.

35. The method of claim 34, in which the HIV-Associated Chronic Diarrhea is caused by *Cryptosporidium* spp.

36. The method of claim 16, in which a non-human animal is treated for secretory diarrhea.

37. The method of claim 36, in which the non-human animal is selected from the group consisting of bovine animals, swine, ovine animals, poultry, equine animals, canine animals and feline animals.

38. The method of claim 37, in which the secretory diarrhea is caused by an agent selected from the group consisting of *Escherichia coli*, *Salmonella* spp., *Clostridium perfringens*, *Bacteriodes fragilis*, *Campylobacter* spp., *Yersinia enterocolitica*, *Cryptosporidium* spp., rotavirus and coronavirus.

39. The method of claim 36, in which the pharmaceutical composition is delivered in animal feed.

40. The method of claim 16, in which the pharmaceutical composition is delivered orally.

41. The method of claim 40 in which the pharmaceutical composition is delivered orally in food.

42. The method of claim 40, in which the human or non-human animal is given between 0.1 and 40 mg/kg per day of the proanthocyanidin polymer composition.

43. A method of treatment for secretory diarrhea in animals, including humans, comprising: administering, to a non-human animal or human suffering from diarrhea, a

WO 98/16111

PCT/US97/18845

pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin polymer composition isolated from a Croton spp. or a Calophyllum spp. or a pharmaceutically acceptable derivative thereof, which is
5 formulated as a suppository for rectal administration in a pharmaceutically acceptable carrier.

44. A method of treatment for secretory diarrhea in animals, including humans, comprising: administering, to a
10 non-human animal or human suffering from diarrhea, (a) a pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin polymer composition isolated from a Croton spp. or a Calophyllum spp. or a pharmaceutically acceptable derivative thereof, and a
15 pharmaceutically acceptable carrier; and (b) a pharmaceutical composition comprising an amount effective to inhibit stomach acid secretion of a compound effective to inhibit stomach acid secretion, and a pharmaceutically acceptable carrier.

20 45. The method of claim 44, in which the pharmaceutical composition containing the proanthocyanidin polymer composition is administered at a time subsequent to the administration of the pharmaceutical composition containing the compound effective to inhibit stomach acid secretion but
25 during the period of inhibition of stomach acid secretion.

46. The method of claim 44, in which the pharmaceutical composition containing the proanthocyanidin polymer composition is administered concurrently with the
30 pharmaceutical composition containing the compound effective to inhibit stomach acid secretion.

47. The method of claim 44, in which the diarrhea is caused by a bacterium.
35

48. The method of claim 47, in which the bacterium is selected from the group of *Escherichia coli*, *Vibrio* spp.,

WO 98/16111

PCT/US97/18845

Campylobacter spp., *Salmonella* spp., *Aeromonas* spp.,
Plesiomonas spp., *Shigella* spp., *Klebsiella* spp., *Citrobacter*
spp., *Yersinia* spp., *Clostridium* spp., *Bacteriodes* spp.,
Staphylococcus spp., and *Bacillus* spp.

5

49. The method of claim 48, in which the bacterium is
either enterotoxigenic *Escherichia coli* or *Campylobacter*
jejuni.

10

50. The method of claim 44, in which the secretory
diarrhea is caused by a non-infectious etiology.

51. The method of claim 50, in which the non-infectious
etiology is selected from the group consisting of non-
15 specific diarrhea, ulcerative colitis, inflammatory bowel
syndrome, and cancers and neoplasias of the gastrointestinal
tract.

52. The method of claim 44, in which the human
20 suffering from diarrhea is an infant or a child.

53. The method of claim 44, in which a human is treated
for HIV-Associated Chronic Diarrhea.

25

54. The method of claim 53, in which the HIV-Associated
Chronic Diarrhea is caused by *Cryptosporidium* spp.

55. The method of claim 44, in which a non-human animal
is treated for secretory diarrhea.

30

56. The method of claim 55, in which the pharmaceutical
composition is delivered in animal feed.

57. The method of claim 44, in which the pharmaceutical
35 composition is delivered orally.

WO 98/16111

PCT/US97/18845

58. The method of claim 57, in which the pharmaceutical composition is delivered orally in food.

59. The method of claim 57, in which the human or non-human animal is given between 0.1 and 40 mg/kg per day of the proanthocyanidin polymer composition.

60. A method of treatment for secretory diarrhea in animals, including humans, comprising: administering, to a non-human animal or human suffering from diarrhea, (a) a pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin polymer composition isolated from a *Croton* spp. or a *Calophyllum* spp. or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier; and (b) a pharmaceutical composition comprising an amount effective to neutralize stomach acid of a compound effective to neutralize stomach acid, and a pharmaceutically acceptable carrier.

61. The method of claim 60, in which the pharmaceutical composition containing the proanthocyanidin polymer composition is administered at a time subsequent to the administration of the pharmaceutical composition containing the compound effective to neutralize stomach acid but during the period in which the stomach acid is neutralized.

62. The method of claim 60, in which the pharmaceutical composition containing the proanthocyanidin polymer composition is administered concurrently with the pharmaceutical composition containing the compound effective to neutralize stomach acid.

63. The method of claim 60, in which the diarrhea is caused by a bacterium.

64. The method of claim 63, in which the bacterium is selected from the group of *Escherichia coli*, *Vibrio* spp.,

WO 98/16111

PCT/US97/18845

Campylobacter spp., *Salmonella* spp., *Aeromonas* spp.,
Plesiomonas spp., *Shigella* spp., *Klebsiella* spp., *Citrobacter*
spp., *Yersinia* spp., *Clostridium* spp., *Bacteriodes* spp.,
Staphylococcus spp., and *Bacillus* spp.

5

65. The method of claim 64, in which the bacterium is
either enterotoxigenic *Escherichia coli* or *Campylobacter*
jejuni.

10

66. The method of claim 60, in which the secretory
diarrhea is caused by a non-infectious etiology.

67. The method of claim 66, in which the non-infectious
etiology is selected from the group consisting of non-
15 specific diarrhea, ulcerative colitis, inflammatory bowel
syndrome, and cancers and neoplasias of the gastrointestinal
tract.

68. The method of claim 60, in which the human
20 suffering from diarrhea is an infant or a child.

69. The method of claim 60, in which a human is treated
for HIV-Associated Chronic Diarrhea.

25 70. The method of claim 69, in which the HIV-Associated
Chronic Diarrhea is caused by *Cryptosporidium* spp.

71. The method of claim 60, in which a non-human animal
is treated for secretory diarrhea.

30

72. The method of claim 71, in which the pharmaceutical
composition is delivered in animal feed.

73. The method of claim 60, in which the pharmaceutical
35 composition is delivered orally.

WO 98/16111

PCT/US97/18845

74. The method of claim 73, in which the pharmaceutical composition is delivered orally in food.

75. The method of claim 73, in which the human or non-
5 human animal is given between 0.1 and 40 mg/kg per day of the proanthocyanidin polymer composition.

76. A method for preventing secretory diarrhea in animals, including humans, comprising: administering, to a
10 non-human animal or human at risk of developing diarrhea, a pharmaceutical composition comprising a prophylactically effective amount of a proanthocyanidin polymer composition isolated from a *Croton* spp. or a *Calophyllum* spp. or a pharmaceutically acceptable derivative thereof formulated to
15 protect the proanthocyanidin polymer composition from the action of stomach acid, and a pharmaceutically acceptable carrier.

77. The method of claim 76, in which the *Croton* spp. is
20 *Croton lechleri*.

78. The method of claim 76, in which the composition comprises an enteric coating.

25 79. The method of claim 78, in which the composition is formulated as a capsule, which capsule is or is not enteric coated.

80. The method of claim 78, in which the enteric
30 coating is comprised of a methacrylic acid-methacrylic acid ester copolymer with acid ionizable groups.

81. The method of claim 80, in which the enteric coating further comprises one or more plasticizer compounds.
35

WO 98/16111

PCT/US97/18845

82. The method of claim 81, in which the plasticizer compounds are polyethylene glycol ester and citric acid ester.

5 83. The method of claim 82, in which the composition is formulated as a compressed tablet.

84. The method of claim 82, in which the composition is formulated as a capsule containing beads, which beads
10 comprise a sugar sphere, a layer of the proanthocyanidin polymer composition and a layer of the enteric coating.

85. The method of claim 82, in which the composition is formulated as a capsule containing microspheres of 300
15 microns to 500 microns, which microspheres comprise granules of the proanthocyanidin polymer composition and a layer of the enteric coating.

86. The method of claim 76 in which the diarrhea to be
20 prevented is caused by a bacterium.

87. The method of claim 86, in which the bacterium is selected from the group of *Escherichia coli*, *Vibrio* spp., *Campylobacter* spp., *Salmonella* spp., *Aeromonas* spp.,
25 *Plesiomonas* spp., *Shigella* spp., *Klebsiella* spp., *Citrobacter* spp., *Yersinia* spp., *Clostridium* spp., *Bacteriodes* spp., *Staphylococcus* spp., and *Bacillus* spp.

88. The method of claim 87, in which the bacterium is
30 either enterotoxigenic *Escherichia coli* or *Campylobacter jejuni*.

89. The method of claim 76, in which the secretory diarrhea is caused by a non-infectious etiology.

35

90. The method of claim 89, in which the non-infectious etiology is selected from the group consisting of non-

WO 98/16111

PCT/US97/18845

specific diarrhea, ulcerative colitis, inflammatory bowel syndrome, and cancers and neoplasias of the gastrointestinal tract.

5 91. The method of claim 76, in which the human at risk of developing diarrhea is an infant or a child.

92. The method of claim 76, in which the diarrhea to be prevented is HIV-Associated Chronic Diarrhea.

10

93. The method of claim 92, in which the HIV-Associated Chronic Diarrhea is caused by *Cryptosporidium* spp.

94. The method of claim 76, in which secretory diarrhea
15 is to be prevented in a non-human animal.

95. The method of claim 94, in which the non-human animal is selected from the group consisting of bovine animals, swine, ovine animals, poultry, equine animals,
20 canine animals, and feline animals.

96. The method of claim 95, in which the secretory diarrhea is caused by an agent selected from the group consisting of *Escherichia coli*, *Salmonella* spp., *Clostridium*
25 *perfringens*, *Bacteriodes fragilis*, *Campylobacter* spp., *Yersinia enterocolitica*, *Cryptosporidium* spp., rotavirus and coronavirus.

97. The method of claim 94, in which the pharmaceutical
30 composition is delivered in animal feed.

98. The method of claim 76, in which the pharmaceutical composition is delivered orally.

35 99. The method of claim 98 in which the pharmaceutical composition is delivered orally in food.

WO 98/16111

PCT/US97/18845

100. The method of claim 99, in which the human or non-human animal is given between 0.1 and 40 mg/kg per day of the proanthocyanidin polymer composition.

5

10

15

20

25

30

35

WO 98/16111

PCT/US97/18845

1/6




FIG. 1

SUBSTITUTE SHEET (RULE 26)

WO 98/16111

PCT/US97/18845

2/6




FIG. 2

SUBSTITUTE SHEET (RULE 26)

WO 98/16111

PCT/US97/18845

3/6





FIG. 3
SUBSTITUTE SHEET (RULE 20)

WO 98/16111

PCT/US97/18845

4/6



SUBSTITUTE SHEET (RULE 28)

WO 98/16111

PCT/US97/18845




FIG. 7




FIG. 6

WO 98/16111

PCT/US97/18845

6/6




FIG. 8

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/18845

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 65/00, 31/08; A61K 9/48, 9/20, 9/22, 9/28

US CL : 424/195.1, 451, 464, 468, 474; 514/732, 867

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/195.1, 451, 464, 468, 474; 514/732, 867

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Remington's Pharmaceutical Sciences, Kirk-Othmer

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS ONLINE, BIOSIS, MEDLINE, DIALOG

search terms: proanthocyanidin, croton, calophyllum, diarrhea, enteric, coat?, suppositor?, Oral?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,211,944 A (TEMPESTA) 18 May 1993. See entire document, particularly, columns 12-14 and column 38, lines 40-52.	1-100
Y	Remington's Pharmaceutical Sciences. Mack Publishing Company. (Easton, Pennsylvania) 1980, Chapter 87, pages 1530-1533 and Chapter 90, pages 1585-1593. See entire document.	1-100
Y	US 4,857,327 A (VIRDLAM) 15 August 1989, see entire document, particularly, column 2, lines 30-35 and column 3, lines 34-40.	16-100
Y	HOR et al. Inhibition of Intestinal Chloride Secretion by Proanthocyanidins from Guazuma ulmifolia. Planta Medica. 1995, Vol. 61, pages 208-212. See entire document.	1-100

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 DECEMBER 1997

Date of mailing of the international search report

29 JAN 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

IRENE MARX

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/18845

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,043,160 A (WURSCH) 27 August 1991. See entire document, especially, column 3, lines 27-44.	1-100
Y	CHEN et al. Studies on the Anti-Tumour, Anti-Bacterial and Wound-Healing Properties of Dragon's Blood. <i>Planta Medica</i> . 1994, Volume 60, pages 541-545. See entire document.	1-100
Y	HOR et al. Proanthocyanidin Polymers with antisecretory activity and proanthocyanidin oligomers from <i>Guazuma Ulmifolia</i> bark. <i>Phytochemistry</i> . 1996, Vol. 42, No. 1, pages 109-119. See entire document.	1-100
Y	NEWMAN et al. High-Resolution ¹³ C NMR Studies of Proanthocyanidin Polymers (Condensed Tannins). <i>Magnetic Resonance in Chemistry</i> . 1987, Volume 25, pages 118-124. See entire document.	1-100
Y	OOMS et al. Pathogenesis and Pharmacology of Diarrhea. <i>Veterinary Research Communications</i> . 1986, Vol. 10, pages 355-397. See entire document.	1-100
Y	PALLENBACH et al. Proanthocyanidins from <i>Quercus petraea</i> Bark. <i>Planta Medica</i> . 1993, Vol. 59, pages 264-268. See entire document.	1-100
Y	PERDUE et al. South American Plants II: Taspine Isolation and Anti-Inflammatory Activity. <i>Journal of Pharmaceutical Sciences</i> . January 1979, Vol. 68, No. 1, pages 124-126	1-100
Y	SILVERSTEIN, L. Procyanidin from Black Bean (<i>Phaseolus vulgaris</i>): Effects on Transport of Sodium, Chloride, Glucose and Alanine in the Rat Ileum. Washington State University: Program in Nutrition (Dissertation). May 1989, pages 1-80. See entire document.	1-100
Y	UBILLAS et al. SP-303, an Antiviral Oligomeric Proanthocyanidin from the Latex of <i>Croton lechleri</i> (Sangre de Drago) <i>Phytomedicine</i> . 1994, Vol. 1, pages 77-106. See entire document.	1-100
Y	CRAIG, C. Shaman Gets Positive Efficacy Data on Diarrhea Drug. <i>BioWorld Today: The Daily Biotechnology Newspaper</i> . 22 August 1996, Vol. 7, No. 164, pages 1-2.	1-100
Y	YOSHIDA et al. Two Polyphenol Glycosides and Tannins from <i>Rosa Cymosa</i> . <i>Phytochemistry</i> 1993, Vol. 32, No. 4, pages 1033-1036. See entire document.	1-100